WO2018020473A1 - Dairy product and process - Google Patents

Dairy product and process Download PDF

Info

Publication number
WO2018020473A1
WO2018020473A1 PCT/IB2017/054610 IB2017054610W WO2018020473A1 WO 2018020473 A1 WO2018020473 A1 WO 2018020473A1 IB 2017054610 W IB2017054610 W IB 2017054610W WO 2018020473 A1 WO2018020473 A1 WO 2018020473A1
Authority
WO
WIPO (PCT)
Prior art keywords
sialyloligosaccharide
sialyllactose
permeate
weight
retentate
Prior art date
Application number
PCT/IB2017/054610
Other languages
French (fr)
Inventor
Alan David WELMAN
Geoffrey Stevens
Christopher Paul Mcjarrow
Bertram Yin FONG
Bing Wang
Original Assignee
Fonterra Co-Operative Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ750365A priority Critical patent/NZ750365A/en
Priority to BR112019001525-6A priority patent/BR112019001525B1/en
Priority to AU2017302181A priority patent/AU2017302181B2/en
Priority to RU2019105567A priority patent/RU2019105567A/en
Priority to JP2019504767A priority patent/JP2019523278A/en
Priority to CN201780046024.2A priority patent/CN109715169A/en
Priority to CA3030809A priority patent/CA3030809A1/en
Priority to SG11201811807XA priority patent/SG11201811807XA/en
Application filed by Fonterra Co-Operative Group Limited filed Critical Fonterra Co-Operative Group Limited
Priority to MX2019000881A priority patent/MX2019000881A/en
Priority to US16/319,213 priority patent/US10729707B2/en
Priority to KR1020197001922A priority patent/KR102502459B1/en
Priority to EP17833689.7A priority patent/EP3490567A4/en
Publication of WO2018020473A1 publication Critical patent/WO2018020473A1/en
Priority to US16/897,117 priority patent/US20200306277A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1206—Lactose hydrolysing enzymes, e.g. lactase, beta-galactosidase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K13/00—Sugars not otherwise provided for in this class
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2210/00—Physical treatment of dairy products
    • A23C2210/20—Treatment using membranes, including sterile filtration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2210/00—Physical treatment of dairy products
    • A23C2210/20—Treatment using membranes, including sterile filtration
    • A23C2210/206—Membrane filtration of a permeate obtained by ultrafiltration, nanofiltration or microfiltration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a method of obtaining
  • sialyloligosaccharides sialyloligosaccharides, sialyloligosaccharide-enriched compositions and the use of sialyloligosaccharides for maintaining or increasing brain function or development.
  • composition of mammalian milk is specifically targeted to support normal growth and development of the infant or child (International Code of Marketing Breastmilk Substitutes, World Health Organization, Geneva, 1981).
  • Maternal formulas, infant formulas, follow-on formulas, growing-up formulas, dietetic products and other dairy containing compositions are typically produced using non-human milk.
  • the nutritional composition of human milk differs in some respects to that of non-human milk.
  • Non-human whole milk such as cow, goat or sheep milk, contains a very different complement of milk oligosaccharides to that of human milk.
  • Optimal cognitive development and growth is a key part of infant and child development. Clearly, impaired cognitive development will have significant effects on quality of life. Additionally, restricted growth has been shown to have detrimental effects on long-term health. Therefore, any agent shown to increase cognitive development or maintain healthy growth will have wide benefits for infants and children (Bryan et a ⁇ ., (2004). Nutrients for cognitive development in school- aged children. Nutr Rev 62: 295-306).
  • Cognitive decline is characterised by reduced learning ability, memory and attention span is widespread among the elderly. Any agent that prevents or delays cognitive decline will have widespread benefits on the quality of life of the elderly.
  • the invention provides a method of producing sialyloligosaccharides from a liquid source that comprises sialyloligosaccharides, carbohydrates and minerals by subjecting the liquid source to a process comprising a) heating the liquid source to a temperature of from about 67°C, b) subjecting the heat-treated liquid source to
  • the invention relates to a sialyloligosaccharide- enriched composition, comprising on a dry solids basis
  • At least about 0.2% by weight neutral oligosaccharides less than about 25% by weight protein and non-protein nitrogen, less than about 80% by weight sugars not including sialyllactose, and less than about 5% by weight ash.
  • the invention relates to a composition for providing nutrition to an infant of less than 6 months of age comprising 3'-sialyllactose, 6'- sialyllactose and sialyllactosamine in a ratio of from about 10: 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
  • the invention relates to a composition for providing nutrition to an infant of from about 6 months to about 12 months of age comprising 3'-sialyllactose, 6'-sialyllactose and sialyllactosamine in a ratio of from about 10 : 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
  • the invention relates to a composition for providing nutrition to an infant of 12 months of age or over comprising 3'-sialyllactose, 6'- sialyllactose and sialyllactosamine in a ratio of from about 10: 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
  • the invention relates to method of treating mild cognitive impairment associated with any one or more of age-related cognitive decline, or cognitive impairment associated with any one or more of Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia comprising administering an effective amount of a si , or a central nervous system
  • treating includes preventing, delaying or ameliorating.
  • the liquid source comprises a combination of two or more sialyloligosaccharide-containing streams.
  • the liquid source comprises mother liquor as a by-product of lactose crystallisation, a dairy permeate, whey, whey permeate, or a combination of any two or more thereof.
  • the heat treatment is carried out at a temperature of from about 67 to about 100°C.
  • the heat treatment of the liquid source is carried out for about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 minutes, and suitable ranges may be selected from between any of these values.
  • the heat treatment of the liquid source precipitates about 2, 3, 4, 5, 6, 7, 8, 9 or 10% of the minerals present in the liquid source, and suitable ranges may be selected from between any of these values.
  • the first permeate comprises
  • the first retentate comprises
  • the filtration step results in a reduction in the amount of insoluble minerals and protein in the first permeate, when compared to the liquid source.
  • the filtration step of (b)(i) is carried out at about 50, 55, 60, 65, 70, 75, 80, 85 or 90°C to produce a first retentate and first permeate, and suitable ranges may be selected from between any of these values.
  • the heat resistant filter of (b)(i) is a ceramic filter.
  • the filtration step of (b)(ii) is carried out at about 55, 60, 65, or about 70°C to produce a first retentate and first permeate, and suitable ranges may be selected from between any of these values.
  • the filtration step of (b)(ii) is carried out using a heat resistant filter.
  • the heat resistant filter of (b)(ii) is a ceramic filter.
  • the heat treated liquid source is subjected to ultrafiltration with a ceramic filter.
  • the ceramic ultrafiltration is conducted at a temperature of from about 50, 55, 60, 65, 70, 75, 80, 85 or 90°C, and suitable ranges may be selected from between any of these values.
  • the ceramic ultrafiltration is conducted at a temperature of from about 60°C to about 80°C.
  • At least one glycoside hydrolase or polymerase enzyme reaction Preferably at least one glycoside hydrolase or polymerase enzyme reaction.
  • a) increases the molecular size of at least one disaccharide in the source to produce at least one oligosaccharide
  • the enzyme comprises ⁇ -galactosidase.
  • the disaccharide comprises lactose.
  • the monosaccharide comprises galactose or glucose.
  • the oligosaccharide comprises one or more
  • the filtration of the light phase is ultrafiltration.
  • the ultrafiltration is conducted at a temperature of from about 50, 55, 60, 65 or 70 °C, and suitable ranges may be selected from between any of these values.
  • the ultrafiltration is conducted at a temperature of from about 55 °C to about 65 °C.
  • the nanofiltration is conducted at a temperature of from about 25, 30, 35, 40, 45, 50 or 55 °C, and suitable ranges may be selected from between any of these values.
  • the ultrafiltration is conducted at a temperature of about 50 °C.
  • the second permeate comprises soluble minerals and at least one monosaccharide or disaccharide.
  • the second retentate comprises
  • the second retentate comprises
  • At least about 0.2% by weight neutral oligosaccharides less than about 5% by weight protein and non-protein nitrogen, less than about 80% by weight non-sialyloligosaccharide sugars, and less than about 5% by weight ash.
  • the second permeate comprises
  • the second retentate is subjected to either nanofiltration or reverse osmosis to produce a third retentate.
  • the concentrated second retentate, or the third retentate is subjected to decolourisation.
  • the method comprises the steps of
  • sialyloligosaccharide-containing extract subjecting the sialyloligosaccharide-containing extract to crystallisation to produce a crystallised sialyloligosaccharide-containing extract, and drying the sialyloligosaccharide-containing extract or crystallised
  • sialyloligosaccharide-containing extract to produce a dried sialyloligosaccharide- containing extract.
  • the sialyloligosaccharide-containing extract comprises less than about 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 3, 2, or 1% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values.
  • the sialyloligosaccharide-containing extract comprises less than about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% by weight ash, and suitable ranges may be selected from between any of these values.
  • the sialyloligosaccharide-containing extract comprises, on a dry solids basis
  • At least about 0.2% by weight neutral oligosaccharides less than about 5% by weight protein and non-protein nitrogen, less than about 80% by weight non-sialyloligosaccharide sugars, and less than about 5% by weight ash.
  • the sialyloligosaccharide-containing extract comprises, on a dry solids basis
  • the invention relates to a sialyloligosaccharide- containing extract produced by any one of the methods described above.
  • the composition comprises, on a dry solids basis, a greater amount of 3'-sialyllactose relative to the amount of 6'-sialyllactose.
  • the composition comprises 3'-sialyllactose and 6'- sialyllactose in a ratio of from about 65: 1 to about 1.5: 1, from about 15 : 1 to about 1.5 : 1, or from about 8 : 1 to about 1.5 : 1, and suitable ranges may be selected from between any of these values.
  • the invention relates to a nutritional formulation comprising a sialyloligosaccharide-containing extract produced by a method as described above, or comprises a sialyloligosaccharide-enriched composition as described above.
  • the nutritional formulation is an infant formula, a follow-on formula, a growing-up formula, a paediatric formula, a human milk fortifier, a children's food or drink, a maternal supplement, a maternal nutritional formulation, a fermented food, a UHT milk, a UHT drinking yoghurt, an acidified milk drink, a UHT powder, a medical food, a sports nutritional formulation, or a formulation for senior or aged populations.
  • the nutritional formulation comprises one or more dairy lipids, one or more galactooligosaccharides, one or more probiotic strains, one or more protein hydrolysates, lactoferrin, a milk fat globular membrane (MFGM) formulation, other prebiotics, or a combination of any two or more thereof.
  • MFGM milk fat globular membrane
  • the nutritional formulation the dairy lipid comprises buttermilk, high fat whey protein concentrate, beta-serum, butter serum, or a combination of any two or more thereof.
  • the probiotic strain comprises a Bifidobacterium lactis or a Lactobacillus rhamnosus strain, or a combination of both Bifidobacterium lactis and Lactobacillus rhamnosus.
  • the Bifidobacterium lactis strain comprises Bifidobacterium lactis HN019 (DR10TM).
  • the Lactobacillus rhamnosus strain comprises Lactobacillus rhamnosus HN001 (DR20TM).
  • the invention relates to a method of maintaining or increasing brain function or brain development, the method comprising
  • the sialyloligosaccharide-containing extract comprises
  • I) maintain or increase the level of gangliosides in the brain, m) maintain or increase blood, nutrient or oxygen flow to the brain, n) maintain or increase synaptogenesis,
  • the subject is a foetal, infant or child subject.
  • the extract, composition or nutritional formulation is administered to a mother during gestation to maintain or increase brain function or development in a foetal subject.
  • the extract, composition or formulation is administered to a breastfeeding mother to maintain or increase brain function or development in an infant subject.
  • the administration of the composition of the invention to an individual leads to an increase in glycerophosphorylcholine (GPC) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • GPC glycerophosphorylcholine
  • suitable ranges may be selected from between any of these values.
  • Glu glutamine
  • the administration of the composition of the invention to an individual leads to an increase in myo inositol (Ins) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • Ins myo inositol
  • composition of the invention leads to a decrease in Lip09 in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • the administration of the composition of the invention to an individual leads to a decrease in macromolecules (MM) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • MM macromolecules
  • the administration of the composition of the invention to an individual leads to an increase in N-Acetylaspartylglutamic acid (NAAG) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • NAAG N-Acetylaspartylglutamic acid
  • the administration of the composition of the invention to an individual leads to an increase in the glutamate-glutamine complex (Glx) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • Glx glutamate-glutamine complex
  • the invention relates to a method of treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age- related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia comprising administering an effective amount of a
  • the invention relates to a sialyloligosaccharide- containing extract produced by a method of any one of claims 1 to 32, a
  • the invention relates to a the use of a
  • sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 32, or a composition of any one of claims 33 to 36 or 44 to 46, in the manufacture of a formulation for treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with
  • This invention may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, and any or all combinations of any two or more of said parts, elements or features, and where specific integers are mentioned herein which have known equivalents in the art to which this invention relates, such known equivalents are deemed to be incorporated herein as if individually set forth.
  • Figure 1 shows a process flow diagram of the method for producing a sialyloligosaccharide-containing extract.
  • Figure 2 shows a graph reporting the results of discrimination tests using a 3 hour "easy" task using an 8-arm radial maze.
  • Figure 3 shows a graph reporting the results of discrimination tests using a 3 hour "more difficult” task using an 8-arm radial maze.
  • Figure 4 shows a graph reporting the results of learning ability on a difficulty tasks using a learning criteria of a maximum of one mistake within four consecutive trials.
  • Figure 5 shows a graph reporting PolySia expression in the frontal cortex in two treatment group compared with control.
  • the present invention relates to a method for the production of sialyloligosaccharide-enriched extracts for use in nutritional formulations including infant formulas.
  • the present invention also provides sialyloligosaccharide-enriched compositions, nutritional formulations comprising such compositions and uses of the compositions and nutritional formulations.
  • compositions and methods of the invention have numerous advantages, including but not limited to the production of a high concentration sialyloligosaccharide composition that is low in impurities.
  • the sialyloligosaccharide-containing liquid source for use in the invention is obtained from mammalian milk. It should be appreciated that any fraction or milk derivative can be utilised in the invention provided it contains
  • the sialyloligosaccharide-containing liquid source is derived from any mammalian milk including but not limited to bovine, sheep, goat, pig, mouse, water buffalo, camel, yak, horse, donkey, llama or human milk fat, with bovine milk being a preferred source.
  • the mammalian milk source is processed to remove at least protein and fat prior to being used in the inventive process.
  • the sialyloligosaccharide-containing source may be generated from upstream milk processes, such as cheese manufacture or casein manufacture that produce a permeate.
  • upstream milk processes include the production of cheese whey, rennet (sweet) whey, or ultrafiltration of skim or raw milk. After ultrafiltration of whey protein the protein is retained in the whey retentate and the whey permeate contains sialyloligosaccharides, lactose and minerals, since sialyloligosaccharides, lactose and minerals pass though the ultrafiltration membrane.
  • the sialyloligosaccharide-containing liquid source (e.g. permeate from upstream dairy processing) may then be processed by one or more filtration steps and may include one or more concentration steps.
  • the sialyloligosaccharide-containing liquid source comprises the permeate resulting from filtration of whole milk, recombined, powdered or fresh skim milk, recombined or reconstituted whole or skim milk powder, skim milk concentrate, skim milk retentate, concentrated milk, ultrafiltered milk retentate, colostrum, whey (including sweet whey, lactic acid whey, mineral acid whey, reconstituted whey powder or deproteinated whey), a composition derived from any milk processing stream, a composition derived from the permeate obtained by ultrafiltration or microfiltration of any milk processing stream, or a combination of any two or more thereof.
  • the sialyloligosaccharide-containing liquid source comprises the permeate from upstream dairy processing processed by one or more filtration steps and/or concentration steps. In one embodiment, the
  • sialyloligosaccharide-containing liquid source comprises the mother liquor produced as a by-product of lactose crystallisation. Following lactose crystallisation, the crystallised lactose is separated from the remaining solution. The remaining solution, the mother liquor (also known as delactosed permeate or Delac), comprises lactose, sialyloligosaccharides and minerals.
  • the mother liquor also known as delactosed permeate or Delac
  • the sialyloligosaccharide-containing liquid source comprises one or more sialyloligosaccharide-containing streams.
  • the sialyloligosaccharide-containing liquid source comprises the mother liquor of lactose crystallisation (delactosed permeate), a dairy permeate, whey, whey permeate, or a combination of any two or more thereof.
  • the sialyloligosaccharide-containing liquid source comprises at least about 0.2, 0.5, 1, 2, 4, 6, 8, 10 or 12% by weight sialyloligosaccharides, and suitable ranges may be selected from between any of these values, (for example, about 0.2 to about 12, about 0.2 to about 8, about 0.2 to about 6, about 0.2 to about 4, about 0.5 to about 12, about 0.5 to about 10, about 0.5 to about 6, about 0.5 to about 2, about 1 to about 12, about 1 to about 10, about 1 to about 4, about 2 to about 12, about 2 to about 8, about 2 to about 6, about 4 to about 12, about 4 to about 10, about 4 to about 6, about 6 to about 12, about 6 to about 10 or about 8 to about 12% by weight sialyloligosaccharides).
  • suitable ranges may be selected from between any of these values, (for example, about 0.2 to about 12, about 0.2 to about 8, about 0.2 to about 6, about 0.2 to about 4, about 0.5 to about 12, about 0.5 to about 10, about 0.5 to about 6, about 0.5 to about
  • the sialyloligosaccharide-containing liquid source comprises less than about 0.01, 0.05, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2 or 2.25% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values, (for example, from about 0.01 to about 2.25, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 0.5, about 0.01 to about 0.3, about 0.01 to about 0.2, about 0.05 to about 2.25, about 0.05 to about 2, about 0.05 to about 1.5, about 0.05 to about 0.75, about 0.05 to about 0.4, about 0.05 to about 0.25, about 0.1 to about 2.25, about 0.1 to about 1.75, about 0.1 to about 1.25, about 0.1 to about 0.75, about 0.1 to about 0.5, about 0.2 to about 2.25, about 0.2 to about 2, about 0.2 to about 0.75, about 0.2 to
  • the sialyloligosaccharide-containing liquid source comprises less than about 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or at least about 75% by weight non-sialyloligosaccharide sugars, and suitable ranges may be selected from between any of these values, (for example, from about 10 to about 75, about 10 to about 70, about 10 to about 65, about 10 to about 60, about 20 to about 75, about 20 to about 70, about 20 to about 65, about 20 to about 60, about 30 to about 75, about 30 to about 70, about 30 to about 65, about 30 to about 60, about 40 to about 75, about 40 to about 70, about 40 to about 65, or about 40 to about 60% by weight non-sialyloligosaccharide sugars).
  • suitable ranges may be selected from between any of these values, (for example, from about 10 to about 75, about 10 to about 70, about 10 to about 65, about 10 to about 60, about 20 to about 75, about 20 to about 70, about 20 to
  • the sialyloligosaccharide-containing liquid source comprises 3'-sialyllactose and 6'-sialyllactose in a ratio of about 65:1, 50:1, 40:1, 30:1, 25:1, 20:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1 or 1.5:1 and suitable ranges may be selected from between any of these values, (for example, from about 65: 1 to about 1.5:1, about 65: 1 to about 1.5:1, about 65:1 to about 3:1, about 65:1 to about 7:1, about 65:1 to about 9:1, about 65:1 to about 13:1, about 65:1 to about 15:1, about 65:1 to about 20:1, about 50:1 to about 1.5:1, about 50:1 to about 1.5:1, about 50:1 to about 3:1, about 50: 1 to about 7:1, about 50: 1 to about 9:1, about 50:1 to about 3:1, about
  • the ratio of 3'-sialyllactose and 6'-sialyllactose is about 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1 or 1.5:1 and suitable ranges may be selected from between any of these values, (for example, from about 15:1 to about 1.5:1, about 12:1 to about 1.5:1, about 10:1 to about 1.5:1, about 8:1 to about 1.5:1, about 7:1 to about 1.5:1, about 6:1 to about 1.5:1, about 5:1 to about 1.5:1, from about 15:1 to about 1:1, about 12:1 to about 1:1, about 10:1 to about 1:1, about 8:1 to about 1:1, about 7:1 to about 1:1, about 6:1 to about 1:1, about 5:1 to about 1:1, about 15:1 to about 2:1,
  • the first step of the method removes at least insoluble minerals and protein from the sialyloligosaccharide-containing source. In some embodiments the first step also removes fat from the sialyloligosaccharide-containing source.
  • the sialyloligosaccharide-containing liquid source is heated to a temperature of at least about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, or at least about 75°C to precipitate minerals in the source.
  • the temperature may be controlled during this step by injection of steam or water, or both steam and water.
  • the sialyloligosaccharide-containing liquid source is heated for a period of at least about 30, 60 or 90 seconds, or at least about 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes. Preferably the heating step is carried out for about 5 min.
  • the heat treatment of the liquid source precipitates about 2, 3, 4, 5, 6, 7, 8, 9 or 10% of the minerals present in the liquid source, and suitable ranges may be selected from between any of these values, (for example, about 2 to about 10, about 2 to about 8, about 2 to about 6, about 3 to about 10, about 3 to about 9, about 3 to about 8, about 3 to about 6, about 4 to about 10, about 4 to about 8, about 4 to about 6%).
  • the sialyloligosaccharide-containing liquid source is subjected to a demineralisation step to remove insoluble minerals from the source.
  • the insoluble minerals including any precipitated minerals produced by heating, are removed by centrifugation.
  • Other suitable methods for removing insoluble minerals may be used as will be readily apparent to those skilled in the art.
  • the demineralisation step also removes protein from the sialyloligosaccharide-containing liquid source.
  • the demineralised liquid source is concentrated using any of the methods described below.
  • filtration is used to remove at least protein. In other embodiments filtration is used to remove at least insoluble minerals and protein.
  • ceramic filtration is used to remove insoluble minerals and protein from the sialyloligosaccharide-containing liquid source.
  • Ceramic filtration separates the protein and insoluble minerals retained in the filtration retentate from the lactose, oligosaccharides and soluble minerals contained in the filtration permeate.
  • the sialyloligosaccharide-containing liquid source is heated to precipitate minerals in the source as described above before ceramic filtration is performed at a temperature of about 35 to about 95°C.
  • the sialyloligosaccharide-containing liquid source is heated to precipitate minerals in the source as described above, followed by centrifugation and then ceramic filtration light phase at a temperature of about 50 to about 70°C is performed.
  • the method comprises ceramic ultrafiltration.
  • the method comprises ceramic filtration using a ceramic membrane comprising aluminium oxide or zirconium oxide.
  • the ceramic filtration is conducted using a membrane having a molecular weight cutoff of at least about 500, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,250, 1,300, 1,400, 1,500, 1,750, 2,000, 2,500, 5,000, 10,000, 15,000, 20,000, 25,000, 30,000, 50,000, 100,000, 150,000 or 200,000 Da and useful ranges may be selected from between any of these values, (for example, from about 500 to about 200,000, about 500 to about 100,000, about 500 to about 30,000, about 500 to about 10,000, about 500 to about 5,000, about 500 to about 2,500, about 500 to about 2,000, about 500 to about 1,500, from about 750 to about 200,000, about 750 to about 100,000, 750 to about 30,000, about 750 to about 10,000, about 750 to about 5,000, about 750 to about 2,500, about 750 to about 2,000, about 750 to about 1,500, from about 1,000 to about 200,000, about 1,000 to about 100,000, about 1,000 to about
  • the ceramic filtration is conducted using a membrane having a pore size of at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.25, 0.4, 0.5, 0.6, 0.75, 0.8, 1, 1.25, 1.4, 1.5, 1.6, 1.75, 1.8, 2, 2.5 or 3 ⁇ and useful ranges may be selected from between any of these values, (for example, from about 0.001 to about 3, about 0.001 to about 2.5, about 0.001 to about 2, 0.001 to about 1.75, 0.001 to about 1.5, about 0.005 to about 3, about 0.005 to about 2.5, about 0.005 to about 2, 0.005 to about 1.75, 0.005 to about 1.5, about 0.01 to about 3, about 0.01 to about 2.5, about 0.01 to about 2, 0.01 to about 1.75, or from about 0.01 to about 1.5 ⁇ ).
  • ceramic filtration is conducted at a temperature of at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95°C, and useful ranges may be selected from between any of these values, (for example, from about 30 to about 95, about 40 to about 95, about 50 to about 95, about 40 to about 90, about 50 to about 90, about 60 to about 90, about 65 to about 90, about 40 to about 85, about 50 to about 85, about 55 to about 85, about 60 to about 90, about 65 to about 90, about 40 to about 80, about 50 to about 80, about 55 to about 80, about 60 to about 80, about 65 to about 80, about 40 to about 75, about 50 to about 75, about 55 to about 75, about 60 to about 75, or about 65 to about 75°C).
  • useful ranges may be selected from between any of these values, (for example, from about 30 to about 95, about 40 to about 95, about 50 to about 95, about 40 to about 90, about 50 to about 90, about 60 to about 90, about 65
  • ceramic filtration is conducted at a pressure of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 bar, and useful ranges may be selected from between any of these values, (for example, from about 1 to about 15, about 2 to about 15, about 3 to about 15, about 1 to about 12, about 3 to about 12, about 1 to about 10, about 3 to about 10, about 1 to about 8, about 2 to about 8, about 3 to about 8, about 1 to about 7, about 2 to about 7, about 3 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 1 to about 5, about 2 to about 5, or about 3 to about 5 bar) .
  • the method comprises ceramic filtration in combination with diafiltration.
  • ultrafiltration or nanofiltration is used to remove at least protein.
  • Filtration may be used to separate the protein, which is retained in the filtration retentate, from saccharides such as lactose and soluble minerals contained in the filtration permeate.
  • ultrafiltration or nanofiltration is used in combination with diafiltration.
  • ultrafiltration is conducted at a temperature of at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90°C, and useful ranges may be selected from between any of these values, (for example, from about 25 to about 90, about 40 to about 90, about 50 to about 90, about 30 to about 85, about 40 to about 85, about 50 to about 85, about 55 to about 85, about 30 to about 80, about 40 to about 80, about 50 to about 80, about 55 to about 80, about 30 to about 75, about 40 to about 75, about 50 to about 75, about 55 to about 75, about 30 to about 70, about 40 to about 70, about 50 to about 70, about 55 to about 70, about 30 to about 65, about 65 to about 75, about 50 to about 65, or about 55 to about 65°C).
  • Suitable membranes for ultrafiltration include polyethersulfone membranes.
  • Other ultrafiltration membranes known in the art may also be suitable as will be apparent to those skilled in the art.
  • ultrafiltration is conducted using a membrane having a molecular weight cutoff of at least about 1,000, 1,500, 2,000, 3,000, 3,500, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 12,500, 15,000, 17,500, 20,000, 25,000 or 30,000 Da, and useful ranges may be selected from between any of these values, for example, (from about 1,000 to about 30,000, about 3,000 to about 30,000, about 5,000 to about 30,000, about 1,000 to about 25,000, about 2,000 to about 25,000, about 3,000 to about 25,000, about 5,000 to about 25,000, about 1,000 to about 20,000, about 2,000 to about 20,000, about 3,000 to about 20,000, about 5,000 to about 20,000, about 10,000 to about 20,000, about 2,000 to about 15,000, about 3,000 to about 15,000, about 5,000 to about 15,000, about 2,000 to about 10,000, about 3,000 to about 10,000, or about 5,000 to about 10,000 Da).
  • ultrafiltration is conducted at a pressure of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 bar, and useful ranges may be selected from between any of these values, (for example, from about 1 to about 15, about 2 to about 15, about 3 to about 15, about 4 to about 15, about 5 to about 15, about 1 to about 12, about 2 to about 10, about 3 to about 10, about 4 to about 10, about 5 to about 10, about 1 to about 8, about 2 to about 8, about 3 to about 8, about 4 to about 8, about 5 to about 8, about 1 to about 7, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 5 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 4 to about 6, about 5 to about 6, about 1 to about 5, about 2 to about 5, about 3 to about 5 or about 4 to about 5 bar).
  • nanofiltration is conducted using a
  • nanofiltration is conducted at a temperature of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75°C, and useful ranges may be selected from between any of these values, (for example, from about 15 to about 75, about 20 to about 75, about 25 to about 75, about 15 to about 70, about 20 to about 70, about 25 to about 70, about 15 to about 65, about 20 to about 65, about 25 to about 65, about 15 to about 60, about 20 to about 60, about 25 to about 60, about 15 to about 55, about 20 to about 55, or about 25 to about 55°C).
  • Suitable membranes for nanofiltration include polyamide-imide membranes or polyamide thin film composite membranes.
  • Suitable polyamide- imide membranes include the Synder ® NF membranes, including the Synder ® NFS, NFX and NFW membranes.
  • Other nanofiltration membranes known in the art may also be suitable as will be apparent to those skilled in the art.
  • nanofiltration is conducted using a
  • membrane having a molecular weight cutoff of at least about 10, 25, 50, 100, 150, 200, 250, 300, 350, 400 or at least about 500 Da may be selected from between any of these values, (for example, from about 10 to about 500, about 50 to about 500, about 100 to about 500, about 10 to about 400, about 50 to about 400, about 100 to about 400, about 10 to about 300, about 50 to about 300, about 100 to about 300, about 10 to about 250, about 50 to about 250, or about 100 to about 250 Da).
  • nanofiltration is conducted at a pressure of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or at least about 75 bar, and useful ranges may be selected from between any of these values, (for example, from about 5 to about 75, about 30 to about 75, about 35 to about 75, about 5 to about 70, about 30 to about 70, about 35 to about 70, about 5 to about 65, about 30 to about 65, about 35 to about 65, about 5 to about 60, about 25 to about 60, about 30 to about 60, about 35 to about 60, about 40 to about 60, about 5 to about 55, about 25 to about 55, about 30 to about 55, about 35 to about 55, about 40 to about 55, about 5 to about 50, about 25 to about 50, about 30 to about 50, about 35 to about 50, about 40 to about 50, about 5 to about 45, about 25 to about 45, about 30 to about 45, about 35 to about 45, or about 40 to about 45 bar).
  • useful ranges may be selected from between any of these values, (for example,
  • Various methods may be used to separate disaccharides, particularly lactose, from sialyloligosaccharides in the sialyloligosaccharide-containing source material.
  • the method comprises an enzyme reaction to increase or decrease the molecular size of one or more disaccharides to produce one or more monosaccharides or oligosaccharides.
  • the reaction product may be subjected to filtration to remove the monosaccharides or oligosaccharides produced by the enzyme reaction.
  • Methods to measure oligosaccharides such as galactooligosaccharides are given by "AOAC official method of 2001. 02 trans-Galactooligosaccharides (TGOS)," in Selected Food Products, AOAC International, Gaithersburg, Md, USA, 2005.” Any suitable method designed for this purpose could also be used. Suitable filtration conditions are discussed above.
  • Filtration conditions for example, membrane pore size or molecular weight cutoff, temperature and pressure, are selected such that the monosaccharides or polysaccharides to be removed are retained in the retentate and the sialyloligosaccharides are contained in the permeate, or vice versa.
  • the enzyme reaction increases the molecular size of the disaccharide to produce one or more polysaccharides.
  • the enzyme reaction decreases the molecular size of the disaccharide to produce one or more monosaccharides.
  • the enzyme is a ⁇ -galactosidase.
  • ⁇ -galactosidase catalyses the hydrolysis of the ⁇ -glycosidic bond between galactose and other sugars.
  • the conditions of the enzyme reaction may be manipulated to produce monosaccharides and/or oligosaccharides.
  • the ⁇ -galactosidase can be sourced from Kluyveromyces fragilis, Aspergillus niger, Aspergillus oryzae, Kluyveromyces lactis, Kluyveromyces spp., Penicillium spp., Rhodotorula spp., Sporobolomyces singularis, Bifidobacterium spp., Bacillus spp., Bacillus circulans, Escherichia coli, Lactobacillus thermophiles,
  • Lactobacillus spp. Lactobacillus spp., Leuconostoc, citrovorum or Enterobacter spp.
  • transglycosylation to produce oligosaccharides may be favoured. It may be necessary to perform a concentration step before an enzyme reaction to promote transglycosylation.
  • the input material (first permeate or deminerliased liquid source) to increase the molecular size of at least one disaccharide comprises at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or at least about 70% disaccharides, particularly lactose. Suitable ranges may be selected from between any of these values, for example, from about 30% to about 70% or from about 40% to about 60%.
  • the input material (first permeate or demineralised liquid source) to an enzyme reaction to decrease the molecular size of at least one disaccharide comprises at least about 5, 10, 15, 20, 25, 30, 35, or 40% by weight disaccharides, particularly lactose. Suitable ranges may be selected from between any of these values, for example, from about 5 to about 40 or from about 20 to about 30% by weight.
  • ⁇ -galactosidase catalyses the production of galactooligosaccharides (GOS) from lactose.
  • the reaction product may be subjected to nanofiltration to remove the GOS.
  • nanofiltration is used to remove GOS and protein.
  • ⁇ -galactosidase catalyses the production of galactose and glucose from lactose.
  • the reaction product may be subjected to nanofiltration to remove the galactose and glucose.
  • nanofiltration removes galactose, glucose and soluble minerals.
  • two or more enzyme reaction steps are conducted.
  • a first enzyme reaction step is conducted to produce one or more monosaccharides.
  • a second enzyme step is conducted to produce one or more oligosaccharides.
  • the first enzyme reaction step is conducted after ceramic filtration. In another embodiment the first enzyme reaction step is conducted after demineralisation, prior to ultrafiltration.
  • the second enzyme reaction step is conducted after nanofiltration and before concentration. 4. Concentration
  • the method comprises one or more steps to concentrate the sialyloligosaccharides.
  • concentration is by removing water. Any concentration process can be used to effect this, such as nanofiltration, reverse osmosis or evaporation. Both reverse osmosis and evaporation may be used.
  • Evaporation for the purpose of concentration may be carried out by any suitable evaporative process.
  • Evaporators such as a falling film evaporator, rising film evaporator, plate evaporator, or multiple effect evaporator may be used .
  • nanofiltration is used in combination with reverse osmosis.
  • reaction product is subjected to
  • Decolourisation to remove impurities that cause discolouration and/or undesirable odours.
  • Decolourisation can be determined by measuring the change in absorbance with a spectrophotometer over the visible range of wavelengths.
  • decolourisation is performed by exposing the liquid stream to activated carbon. A subsequent filtration step is conducted to remove the activated carbon from the stream. Decolourisation may be conducted as a batch or continuous process.
  • decolourisation is conducted at a
  • temperature of at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or at least about 95°C and useful ranges may be selected from between any of these values, (for example, from about 25 to about 95, about 40 to about 95, about 50 to about 95, or about 55 to about 95°C).
  • At least one concentration step is performed to produce the sialyloligosaccharide-containing extract.
  • the sialyloligosacchande-containing extract may be dried using suitable methods known in the art.
  • the extract is subjected to crystallisation before drying.
  • the extracts and compositions of the invention are enriched in sialyloligosacchandes and neutral oligosaccharides and are low in impurities such as lactose, protein and minerals.
  • Sialyloligosacchandes are oligosaccharides comprising at least one sialic acid moiety.
  • Sialic acids are N- or O-substituted derivatives of neuraminic acid.
  • Mammalian milk comprises both free sialyloligosacchandes and
  • sialyloligosacchandes bound to glycoproteins and/or glycolipids are sialyloligosacchandes bound to glycoproteins and/or glycolipids.
  • the composition contains free sialic acid.
  • the composition or extract comprises 3'- sialyllactose, 6'-sialyllactose, disialyllactose, sialyllactosamine or a combination of any two or more thereof.
  • the composition or extract comprises 3'-sialyllactose, 6'-sialyllactose, disialyllactose and sialyllactosamine.
  • the extract or composition comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35 or 40% by weight sialyloligosacchandes as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40, about 10 to about 40, about 1 to 35, about 5 to about 35, about 7 to about 35, about 10 to about 35, about 1 to about 30, about 5 to about 30, about 7 to about 30, about 10 to about 30, about 1 to about 25, about 5 to about 25, about 7 to about 25, about 10 to about 25, about 1 to about 20, 5 to about 20, about 7 to about 20, about 10 to about 20, about 1 to about 15, about 5 to about 15, about 7 to about 15 or from about 10 to about 15% by weight sialyloligosacchandes).
  • suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40, about 10 to about 40
  • the composition or extract comprises at least about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35 or 40% by weight 3'-sialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40, about 10 to about 40, about 1 to 35, about 5 to about 35, about 7 to about 35, about 10 to about 35, about 1 to about 30, about 5 to about 30, about 7 to about 30, about 10 to about 30, about 1 to about 25, about 5 to about 25, about 7 to about 25, about 10 to about 25, about 1 to about 20, 5 to about 20, about 7 to about 20, about 10 to about 20, about 1 to about 15, about 5 to about 15, about 7 to about 15 or from about 10 to about 15% by weight 3'-sialyllactose).
  • suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40,
  • the composition or extract comprises at least about 0.1, 0.5, 0.75, 1, 1.25, 1.5, 1.75., 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 15, 17 or 20% by weight 6'-sialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.1 to about 20, about 0.1 to about 15, about 0.1 to about 12, about 0.1 to about 10, about 0.1 to about 8, about 0.5 to about 20, about 0.5 to about 15, about 0.5 to about 12, about 0.5 to about 10, about 0.5 to about 8, about 1 to about 20, about 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 8, about 1.5 to about 20, about 1.5 to about 15, about 1.5 to about 12, about 1.5 to about 10, about 1.5 to about 8, about 2 to about 20, about 2 to about 15, about 2 to about 12, about 2 to about 10, about 2 to about 8, about 2.5 to about 20, about 2.5 to about 15, about 2.5 to about about
  • the extract or composition comprises at least about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.075, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2% by weight disialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.001 to about 2, about 0.001 to about 1, about 0.005 to about 1.5, about 0.005 to about 1, about 0.01 to about 2, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 1, about 0.01 to about 0.75, about 0.02 to about 2, about 0.02 to about 1.5, about 0.02 to about 1.25, about 0.02 to about 1, about 0.02 to about 0.75, about 0.03 to about 2, about 0.03 to about 1.5, about 0.03 to about 1.25, about 0.03 to about 1, about 0.03 to about 0.75, about 0.05 to about 2, about 0.05 to about 2, about 0.05 to about
  • the extract or composition comprises at least about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.075, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, or at least about 2% by weight sialyllactosamine as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.001 to about 2, about 0.001 to about 1, about 0.005 to about 1.5, about 0.005 to about 1, about 0.01 to about 2, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 1, about 0.01 to about 0.75, about 0.02 to about 2, about 0.02 to about 1.5, about 0.02 to about 1.25, about 0.02 to about 1, about 0.02 to about 0.75, about 0.03 to about 2, about 0.03 to about 1.5, about 0.03 to about 1.25, about 0.03 to about 1, about 0.03 to about 0.75, about 0.05 to about 2, about
  • the extract or composition comprises, on a dry solids basis, a greater amount of 3'-sialyllactose relative to the amount of 6'- sialyllactose.
  • the extract or composition comprises 3'- sialyllactose and 6'-sialyllactose in a ratio of about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1 or 1:2 and suitable ranges may be selected from between any of these values, (for example, from about 10:1 to about 1:1, about 8:1 to about 1:1, about 7: 1 to about 1:1, about 6:1 to about 1:1, about 5: 1 to about 1:1, about 15:1 to about 2:1, about 12:1 to about 2:1, about 10:1 to about 2:1, about 8:1 to about 2:1, about 7:1 to about 2:1, about 6:1 to about 2:1, about 5:1 to about 2:1, about 15:1 to about 3:1, about 12:1 to about 3:1, about 10:1 to about 3:1, about 8:1 to about 3:1, about 7: 1 to about 3:1, about 6: 1 to about 3:1, or about 5: 1 to about 3:1.
  • suitable ranges may be selected from between any of these values, (for example, from
  • composition or extract further comprises other sialic acid-containing compounds including milk fat globular membrane (MFGM), sialic acid-containing protein and gangliosides.
  • MFGM milk fat globular membrane
  • sialic acid-containing protein sialic acid-containing protein
  • gangliosides sialic acid-containing compounds
  • sialic acid containing compounds includes compounds such as lipids, and protein that contain bound sialic acid.
  • sialic acid containing compounds present in the compositions or extracts described herein include proteins and gangliosides.
  • Milk fat globular membrane is an example of a source of sialic acid containing compounds present in the compositions and extracts described herein.
  • the composition or extract comprises at least about 0.5% of other sialic acid containing compounds as a percentage of the total solids.
  • compositions and extracts further comprise neutral
  • composition or extract comprises added neutral oligosaccharides.
  • Neutral oligosaccharides are oligosaccharides that have no charge.
  • Neutral oligosaccharides present in the compositions of the invention include galactooligosaccharides, fructooligosaccharides, N-acetyllactosamine, N- acetylgalactosaminylglucose, N-acetylgalactosaminyllactose, isoglobotriose, 3'- galactosyllactose, 4'-galactosyllactose, 6'-galactosyllactose, novo-lacto-N- pentaose-I, Lacto-N-neotetraose, and Lacto-N-neohexaose.
  • Fructooligosaccharides can be detected by methods such as described in Cuany, Denis, Thierry Benet, and Sean Austin. 2010 Journal of AOAC International 93 (10)
  • the composition contains added neutral oligosaccharides.
  • the extract or composition comprises at least about 0.01, 0.05, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25 or 30% by weight neutral oligosaccharides, and suitable ranges may be selected from between any of these values, (for example, from about 0.01 to about 30, about 0.01 to about 20, about 0.01 to about 15, about 0.01 to about 10, about 0.01 to about 6, 0.01 to about 2, about 0.01 to about 0.5, about 0.05 to about 30, about 0.05 to about 25, about 0.05 to about 20, about 0.05 to about 15, about 0.05 to about 10, about 0.1 to about 30, about 0.1 to about 25, about 0.1 to about 20, about 0.1 to about 15, about 0.1 to about 10, about 0.2 to about 30, about 0.2 to about 25, about 0.2 to about 20, about 0.2 to about 15, about 0.2 to about 10, about 0.25 to about 30, about 0.25 to about 25, about 0.25 to about 20, about 0.25 to about 15, about 0.25 to about 10, about 0.5 to about 30, about
  • the extract or composition comprises less than about 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 20, about 1 to about 15, about 1 to about 10, about 1 to about 8, about 1 to about 6, about 1 to about 5, about 2 to about 20, about 2 to about 16, about 2 to about 11, about 2 to about 9, about 2 to about 8, about 2 to about 7, about 3 to about 20, about 3 to about 15, about 3 to about 13, about 3 to about 9, about 3 to about 8, about 3 to about 6, about 4 to about 20, about 4 to about 15, about 4 to about 10, about 4 to about 9, about 4 to about 8, about 4 to about 7, about 5 to about 2,0 5 to about 16, about 5 to about 10, about 5 to about 8, about 5 to about 7, about 6 to about 20, about 6 to about 17, about 6 to about 11, about 6 to about 10, about 6 to about 9, about 7 to about 20, about 7 to about 15, about 7 to about 10, about 8 to about
  • non-sialyloligosaccharide sugars refers to all sugars in the composition except for sialyloligosaccharides.
  • Non- sialyloligosaccharide sugars include disaccharides (particularly lactose),
  • oligosaccharides including neutral oligosaccharides and acidic oligosaccharides.
  • the extract or composition comprises less than about 85, 84, 83, 82, 81, 80, 79, 78, 77, 75, 70, 65, 60, 55, 50, 45, 40, 35, or 30% by weight non-sialyloligosaccharide sugars, and suitable ranges may be selected from between any of these values, (for example, from about 30 to about 85, about 30 to about 80, about 30 to about 75, about 40 to about 85, about 40 to about 80, about 40 to about 75, about 50 to about 85, about 50 to about 80, about 50 to about 75, about 50 to about 70, about 55 to about 85, about 55 to about 80, about 55 to about 75, about 55 to about 70, about 60 to about 85, about 60 to about 80, about 60 to about 75, about 60 to about 70, about 65 to about 85, about 65 to about 80, about 65 to about 75, about 65 to about 70, about 70 to about 85, about 70 to about 80, or from about 70 to about 75% by weight non- si
  • the extract or composition comprises less than about 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or less than about 1% by weight ash, and suitable ranges may be selected from between any of these values, (for example, from about 0 to about 15, about 0 to about 12, about 0 to about 10, about 0 to about 7, about 0 to about 5, 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 7, about 1 to about 5, about 2 to about 15, about 2 to about 12, about 2 to about 10, about 2 to about 7, about 3 to about 15, about 3 to about 12, about 3 to about 10, about 3 to about 7, about 4 to about 15, about 4 to about 12, about 4 to about 10, about 4 to about 7, about 5 to about 15, about 5 to about 12, or about 5 to about 10% by weight ash).
  • suitable ranges may be selected from between any of these values, (for example, from about 0 to about 15, about 0 to about 12, about 0 to about 10, about 0 to about 7, about 0 to about 5, 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 7, about
  • the extracts and compositions of the invention are suitable for use in nutritional formulations including maternal formulas, infant formulas, follow-on formulas, growing-up formulas, paediatric formulas, human milk fortifiers, children's foods or drinks, maternal supplements, maternal nutritional formulations, fermented foods, UHT milks, UHT drinking yoghurts, acidified milk drinks, UHT powders, medical foods, sports nutritional formulations, or formulations for senior or aged populations.
  • the term "maternal formula” as used in this specification means a composition for pregnant woman to take during pregnancy.
  • infant formula as used in this specification means a composition for infants aged between 0 days and 6 months old.
  • follow-on formula as used in this specification means a composition for infants aged 6 months to 1 year.
  • growing up formula as used in this specification means a composition for infants and children aged 1 year upwards.
  • Growing-up formula includes growing-up milk powders or GUMPs.
  • the term “paediatric formula” as used in this specification means a composition for children aged from birth.
  • infant formula can vary from child to child depending on the individual's development.
  • follow-on formula can vary from child to child depending on the individual's development.
  • growing-up formula can vary from child to child depending on the individual's development.
  • These products may be in liquid form as concentrates or ready-to-drink liquids or provided as powder concentrates.
  • the nutritional formulation comprises at least about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4 or 5% of the sialyloligosaccharide- containing extract or composition, and suitable ranges may be selected from between any of these values, (for example, from about 0005 to about 5, about 0.005 to about 3, about 0.005 to about 1, about 0.005 to about 0.5, about 0.005 to about 0.05, about 0.01 to about 5, about 0.01 to about 3, about 0.01 to about 1, about 0.01 to about 0.5, about 0.01 to about 0.1, about 0.05 to about 5, about 0.05 to about 4, about 0.05 to about 1, about 0.05 to about 0.1, about 0.1 to about 5, about 0.1 to about 4, about 0.1 to about 1, about 0.1 to about 0.5, about 0.5 to about 5, about 0.5 to about 3, about 0.5 to about 1, about 1 to about 5, about 1 to about 4, about 1 to about 3, about 2 to about 5, about 2 to about 4, about 3 to about 5% of the sialyloli
  • the nutritional formulation comprises at least about 0.005% total sialyloligosaccharides on a weight/volume basis.
  • the infant formula comprises at least about 0.17% total sialyloligosaccharides on a weight/weight solids basis.
  • the follow-on formula comprises at least about 0.19% total sialyloligosaccharides on a weight/weight solids basis.
  • the growing-up formula comprises at least about 0.19% total sialyloligosaccharides on a weight/weight solids basis.
  • the maternal formula comprises at least about 0.15% total sialyloligosaccharides on a weight/weight solids basis.
  • infant formulas refer to nutritional formulas for infants aged 0-6 months, follow-on formula for infants aged 6 months to 1 year, growing up formula for infants aged 12 months onwards. Maternal formulas are for woman trying to conceive, pregnant, or breastfeeding.
  • Nutritional formulations comprising the sialyloligosaccharide extracts and compositions described herein may be incorporated into formulations known in the art. Suitable formulations and ingredients will be apparent to those skilled in the art.
  • the extract or composition delivers more humanised milk-based nutrition in relation to, for example, 3'-sialyllactose.
  • “More humanised” means that the extract or composition is compositionally or functionally more similar to human breast milk than the unmodified or unprocessed form of the source material in relation to, for example, 3'-sialyllactose.
  • One example of the increased humanisation of the extract or composition is in relation to >3-4 months post-partum infants through the ratio of 3'-sialyllactose and 6'-sialyllactose.
  • the applicant has determined that the complement and concentration of sialyloligosaccharides for infants and children varies at different ages and stages of development. In particular, the ratio of 3'-sialyllactose and 6'-sialyllactose varies as the infant or child develops.
  • the optimal ratio of 3'-sialyllactose and 6'- sialyllactose may be administered in compositions specifically tailored for infants or children in particular age groups or developmental stages.
  • composition provides a greater amount of 3'- sialyllactose than 6'-sialyllactose infants aged 4-6 months and above.
  • the composition provides nutrition to an infant of less than 3 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5: 1.
  • the composition is an infant formula.
  • the composition is a composition for providing nutrition to an infant of less than 6 months of age comprising 3'- sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5 : 1.
  • the composition is an infant formula.
  • the composition is a composition for providing nutrition to an infant of from about 6 months to about 12 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5 : 1.
  • the composition is an follow-on formula.
  • the composition is a composition for providing nutrition to an infant of 12 months of age or over comprising 3'- sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1 : 2.
  • the composition is a growing up formula or a paediatric formula.
  • a paediatric formula is given by way for example below.
  • Vitamin B6 51.5 ⁇ g
  • Vitamin B12 0.5 ⁇ g
  • Vitamin D3 0.9 ⁇ g
  • Nutritional formulations, sialyloligosaccharide-containing extracts or compositions described herein may be administered to maintain or increase brain function or development in a normal subject.
  • Subjects who may benefit from administration of the formulations or compositions include neonates, infants, toddlers, children, pregnant women, breastfeeding mothers, adults, athletes, other sportspersons or the elderly.
  • normal subject refers to a subject who is not suffering from a disease or condition associated with impaired brain function or development.
  • an "effective amount” is the amount required to confer therapeutic, prophylactic effect.
  • the interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich, et al. (1966).
  • Body surface area can be approximately determined from height and weight of the subject. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537. Effective doses also vary, as recognized by those skilled in the art, dependent on route of administration, carrier usage, and the like.
  • preventing the decline of or maintaining brain function maintaining normal brain development or preventing delay in brain development.
  • These terms include preventing delayed brain development, maintaining the viability or function of neuronal cells, maintaining cognitive development, preventing delayed cognitive development, maintaining cognitive performance, preventing cognitive decline, maintaining or preventing decline of learning ability, memory or attention span, maintaining the ability of a subject to cope with stress, maintaining the level of gangliosides in the brain, maintaining the level of protein-bound sialic acid in the brain e.g. Neural Cell Adhesion Molecule (NCAM), maintaining blood, nutrient or oxygen flow to the brain, maintaining synaptogenesis, maintaining the activity of the gut/brain axis, or maintaining neurogenesis.
  • NCAM Neural Cell Adhesion Molecule
  • the terms "to increase brain health or development” or “increasing brain health and development” are used interchangeably herein and generally refer to enhancing or improving brain function and advancing brain development. These terms include increasing cognitive development or
  • NCAM Neural Cell Adhesion Molecule
  • Optimal cognitive development is a key part of infant and child development. Therefore any agent shown to increase cognitive development will have wide benefits for infants and children.
  • methodology useful for the assessment of cognitive development in non-human subjects includes the Morris Water Maze Test and the Novel Object Recognition Task Test, as described in Example 1.
  • methodology useful for the assessment of cognitive development in human subjects includes the tools summarised in Table 1. Table 1 - Examples of methods for assessment of human development
  • the administration of the composition of the invention to an individual leads to an increase in glycerophosphorylcholine (GPC) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • GPC glycerophosphorylcholine
  • suitable ranges may be selected from between any of these values.
  • Glu glutamine
  • the administration of the composition of the invention to an individual leads to an increase in myo inositol (Ins) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • Ins myo inositol
  • composition of the invention leads to a decrease in Lip09 in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • the administration of the composition of the invention to an individual leads to a decrease in macromolecules (MM) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • MM macromolecules
  • the administration of the composition of the invention to an individual leads to an increase in N-Acetylaspartylglutamic acid (NAAG) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • NAAG N-Acetylaspartylglutamic acid
  • the administration of the composition of the invention to an individual leads to an increase in the glutamate-glutamine complex (Glx) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
  • Glx glutamate-glutamine complex
  • the extract or composition of the present invention can be used to treat or improve diseases that include cognitive decline as a symptom.
  • the use of the extract or composition can reduce the rate of cognitive decline, maintain cognition in the patient, or improve cognitive ability in that patient.
  • diseases that include cognitive decline as a symptom of that disease include Alzheimer's disease, Parkinson's disease, Huntington's disease or dementia.
  • the invention relates to the use of a extract or composition as described in the treatment or prevention of cognitive decline associated with any one or more or age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia
  • CNS central nervous system
  • Sialyloligosaccharide-containing extracts are produced using four different methods. The sialyloligosaccharide, protein, non-protein nitrogen, lactose and ash content is determined.
  • a sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
  • the source material is heated at greater than 67°C for at least two minutes to precipitate minerals in the mother liquor. Insoluble minerals and some protein are removed by centrifugation.
  • the demineralised source material is subjected to an enzyme reaction step with ⁇ -galactosidase to degrade lactose to galactose and glucose.
  • Ultrafiltration is performed at 50°C to 70°C, 2-10 bar using a membrane with a pore size of 3-20 kDa to remove protein.
  • the ultrafiltration permeate comprising saccharides, soluble minerals and sialyloligosaccharides is subjected to nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove galactose, glucose and soluble minerals.
  • the nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate.
  • reverse osmosis and/or nanofiltration are performed prior to evaporation.
  • a second enzyme reaction is conducted using ⁇ - galactosidase to produce glucose and galactose or to produce GOS.
  • the concentrated retentate or enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
  • the liquid extract is optionally dried to produce a dried extract.
  • the liquid extract is crystallised before drying.
  • a sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
  • the source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor. Insoluble minerals and some protein are removed by centrifugation.
  • the demineralised source material is subjected to ultrafiltration performed at 50-70°C, 2-10 bar using a membrane with a pore size of 3-20 kDa to remove protein.
  • the ultrafiltration permeate comprising sugars, soluble minerals and sialyloligosaccharides is subjected to nanofiltration/diafiltration performed at 25°C- 55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove small sugars and soluble minerals.
  • the nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate.
  • reverse osmosis and/or nanofiltration are performed prior to evaporation.
  • An enzyme reaction is conducted using ⁇ -galactosidase to produce glucose and galactose or to produce GOS.
  • the enzyme product is subjected to decolourisation and filtration to produce a sialyloligosaccharide-enriched liquid extract.
  • the liquid extract is optionally dried to produce a dried extract.
  • the liquid extract is crystallised before drying.
  • a sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
  • the source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor.
  • the source material is subjected to ceramic filtration performed at 50°C to 90°C, 1-6 bar using a membrane with a pore size/MWCO of 300 Da to 2 m to remove insoluble minerals and protein.
  • the demineralised, deproteinised material is subjected to an enzyme reaction step with ⁇ -galactosidase to degrade lactose to galactose and glucose.
  • the material is subjected to nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove galactose, glucose and soluble minerals.
  • the nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate.
  • reverse osmosis and/or nanofiltration are performed prior to evaporation.
  • a second enzyme reaction is conducted using ⁇ - galactosidase to produce glucose and galactose or to produce GOS.
  • the concentrated retentate or enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
  • the liquid extract is optionally dried to produce a dried extract.
  • the liquid extract is crystallised before drying. 4. Method D
  • a sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
  • the source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor.
  • the source material is subjected to ceramic filtration performed at 50-90°C, 1-6 bar using a membrane with a pore size/MWCO of 300 Da to 2 ⁇ to remove insoluble minerals and protein.
  • nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove sugars and soluble minerals.
  • the nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate.
  • reverse osmosis and/or nanofiltration are performed prior to evaporation.
  • a second enzyme reaction is conducted using ⁇ -galactosidase to produce glucose and galactose or to produce GOS.
  • the enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
  • the liquid extract is optionally dried to produce a dried extract.
  • the liquid extract is crystallised before drying.
  • composition of the sialyloligosaccharide-enriched extracts produced by methods A-D is set out in Table 1.
  • Table 1 Composition of sialyloligosaccharide-containing extracts produced by methods A-D
  • the newborn piglet similar to humans, is less developed and its body weight is relatively small in relation to its mature weight. For this reason, both newborn piglets and low-birth-weight infants are vulnerable to developmental deficits post-partum. It has been reported that naturally farrowed piglets born small for gestational age (SGA) (0.7-1.0 kg BW) have spatial learning deficits and abnormal development of white matter (Radlowski et a/., PLoS One, 2014. 9(3) : p. e91951). The piglet is a tractable translational model that can be used to
  • the piglet's digestive system shares similar physiology and anatomical structure with human infants, and has comparable nutrient requirements.
  • the trial groups are described in Table 2.
  • the piglets were housed two per pen in a temperature-conditioned room on a 12-h light (08 : 00-20 : 00) and dark (20: 00-08 : 00) cycle.
  • MRS was performed using a localised single-voxel spin echo Point RESolved spectroscopy (PRESS) sequence.
  • the TE of the SE in this PRESS sequence is equal to YI +Y2+Y3+Y 4 .
  • the TR was 2000 ms, there were three TE used : 35 ms ( Figure I B), 135 ms ( Figure 1C) and 270 ms ( Figure I D) .
  • Cerebra l development was assessed using 3D volumetric MRI to quantify the absolute volume of cerebral white matter, cortical gray matter and basal structures such as the striatum.
  • Diffusion weighted-imaging DWI
  • DTI diffusion-tensor imaging
  • Group 3 showed a significant increase in the absolute levels of glutamate (Glu), myo-inositol (Ins) and glutamate+glutamine (Glx). In addition, there was a significant positive correlation between frontal lobe Ins, N- acetylaspartate (NAA), total NAA, total choline (TCho), total glutathione (Glth), phosphorylcholine (PCh) and total white matter volume or whole brain volume (P ⁇ 0.01).
  • NAA N- acetylaspartate
  • Tho total choline
  • Glth total glutathione
  • PCh phosphorylcholine
  • P ⁇ 0.01 total white matter volume or whole brain volume
  • Glutamate is the brain's major excitatory neurotransmitter, and plays an important role in frontal-hippocampal mechanism of learning and memory.
  • Myo-inositol has been implicated in a role in brain development including learning and memory. Abnormally low myo-inositol and glutamate levels in the hippocampus and amygdala have been detected in patients with depression. Glutamate levels in the medial prefrontal cortex and amygdala have significant correlations with executive function and those in the hippocampus with memory function (Shirayama Y et a/., Myo-inositol, Glutamate, and Glutamine in the
  • Significantly reduced concentrations of hippocampal absolute myo-inositol have been detected in patients at high risk for psychosis (Bakker et a/., Hippocampal myo-inositol and glutamate concentrations are predictive of positive symptom severity in ultra-high risk for psychosis. 2013 European Neuropschoparmacology 23; 2 : page S448).
  • GPC glycerylphosphorylcholine
  • sialyloligosaccharides can alter many important brain metabolites and neurotransmitters required for optimising neurodevelopment in piglets.
  • PolySia The level of polysialic acid (polySia) was measured.
  • PolySia is a unique polymer of sialic acid that modifies neural cell adhesion molecule (NCAM) spatiotemporally in embryonic brains, and is involved in cell migration, neural outgrowth, axonal guidance, synaptic plasticity, and the development of normal neural circuits and neurogenesis.
  • NCAM neural cell adhesion molecule
  • PolySia expression is found in the olfactory bulb, hippocampus, subventricular zone, thalamus, prefrontal cortex, and amygdala, where neural plasticity, remodeling of neural connections, or neural generation is ongoing.
  • PolySia may regulate various neurologically active molecules, such as neurotrophic factor (BDNF), growth factor (FGF2), and neurotransmitter

Abstract

A method of producing sialyloligosaccharides a sialyloligosaccharides-containing source that also contains carbohydrates and minerals. The process includes subjecting the source to a temperature of from about 67°C and (i) filtration with a heat-resistant filter at a temperature of about 35 to about 95°C to produce a first retentate and first permeate, or (ii) centrifugal separation to produce a light phase and a heavy phase and filtration of the light phase at a temperature of about 50 to about 70°C to produce a first retentate and first permeate, (b) nanofiltration of the first permeate, or nanofiltration and diafiltration of the first permeate, to produce a second retentate and second permeate, and (c) concentration of the second retentate, to produce a sialyloligosaccharide-containing extract. Additionally, the invention relates to a sialyloligosaccharide-enriched composition comprising at least 3'-sialyllactose and 6'-sialyllactoseand its use in, for example, nutritional and infant formulas, and for maintaining or improving cognitive function.

Description

DAIRY PRODUCT AND PROCESS
FIELD OF THE INVENTION
[0001] The present invention relates to a method of obtaining
sialyloligosaccharides, sialyloligosaccharide-enriched compositions and the use of sialyloligosaccharides for maintaining or increasing brain function or development.
BACKGROUND TO THE INVENTION
[0002] The composition of mammalian milk is specifically targeted to support normal growth and development of the infant or child (International Code of Marketing Breastmilk Substitutes, World Health Organisation, Geneva, 1981).
[0003] Maternal formulas, infant formulas, follow-on formulas, growing-up formulas, dietetic products and other dairy containing compositions are typically produced using non-human milk. However, the nutritional composition of human milk differs in some respects to that of non-human milk. Non-human whole milk such as cow, goat or sheep milk, contains a very different complement of milk oligosaccharides to that of human milk.
[0004] Optimal cognitive development and growth is a key part of infant and child development. Clearly, impaired cognitive development will have significant effects on quality of life. Additionally, restricted growth has been shown to have detrimental effects on long-term health. Therefore, any agent shown to increase cognitive development or maintain healthy growth will have wide benefits for infants and children (Bryan et a\., (2004). Nutrients for cognitive development in school- aged children. Nutr Rev 62: 295-306).
[0005] Cognitive decline is characterised by reduced learning ability, memory and attention span is widespread among the elderly. Any agent that prevents or delays cognitive decline will have widespread benefits on the quality of life of the elderly.
[0006] It is an object of the present invention to provide a method of obtaining sialyloligosaccharides, sialyloligosaccharide-enriched compositions and the use of sialyloligosaccharides for maintaining or increasing brain function or development, or to at least provide the public with a useful choice. SUMMARY OF THE INVENTION
[0007] In a first aspect, the invention provides a method of producing sialyloligosaccharides from a liquid source that comprises sialyloligosaccharides, carbohydrates and minerals by subjecting the liquid source to a process comprising a) heating the liquid source to a temperature of from about 67°C, b) subjecting the heat-treated liquid source to
(i) a filtration step with a heat-resistant filter at a temperature of about 35 to about 95°C to produce a first retentate and first permeate, or
(ii) centrifugal separation to produce a light phase and a heavy phase and filtration of the light phase with a heat-resistant filter at a temperature of about 35 to about 95°C to produce a first retentate and first permeate,
c) subjecting the first permeate to nanofiltration, or nanofiltration and diafiltration, to produce a second retentate and second permeate, and d) concentrating the second retentate,
to produce a sialyloligosaccharide-containing extract.
[0008] In a further aspect the invention relates to a sialyloligosaccharide- enriched composition, comprising on a dry solids basis
at least about 5% by weight total sialyloligosaccharides comprising o at least about 5% 3'-sialyllactose by weight of total sialyloligosaccharides,
o at least about 2% 6'-sialyllactose by weight of total sialyloligosaccharides,
o at least about 0.01% disialyllactose by weight of total sialyloligosaccharides,
o at least about 0.01% sialyllactosamine by weight of total
sialyloligosaccharides, and
at least about 0.5% by weight free sialic acid,
at least about 0.2% by weight neutral oligosaccharides, less than about 25% by weight protein and non-protein nitrogen, less than about 80% by weight sugars not including sialyllactose, and less than about 5% by weight ash.
[0009] In a further aspect the invention relates to a composition for providing nutrition to an infant of less than 6 months of age comprising 3'-sialyllactose, 6'- sialyllactose and sialyllactosamine in a ratio of from about 10: 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
[OOIO] In a further aspect the invention relates to a composition for providing nutrition to an infant of from about 6 months to about 12 months of age comprising 3'-sialyllactose, 6'-sialyllactose and sialyllactosamine in a ratio of from about 10 : 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
[OOll] In a further aspect the invention relates to a composition for providing nutrition to an infant of 12 months of age or over comprising 3'-sialyllactose, 6'- sialyllactose and sialyllactosamine in a ratio of from about 10: 1 : 0.5 to about 1.5 : 1 : 0.03 3'-sialyllactose to 6'-sialyllactose.
[0012] In a further aspect the invention relates to method of treating mild cognitive impairment associated with any one or more of age-related cognitive decline, or cognitive impairment associated with any one or more of Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia comprising administering an effective amount of a sialyloligosaccharide-containing extract.
[0013] As used herein, "treating" includes preventing, delaying or ameliorating.
[0014] Any one or more of the following embodiments may relate to any of the aspects described herein or any combination thereof.
[0015] Preferably the liquid source comprises a combination of two or more sialyloligosaccharide-containing streams. [0016] Preferably the liquid source comprises mother liquor as a by-product of lactose crystallisation, a dairy permeate, whey, whey permeate, or a combination of any two or more thereof.
[0017] Preferably the heat treatment is carried out at a temperature of from about 67 to about 100°C.
[0018] Preferably the heat treatment of the liquid source is carried out for about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 minutes, and suitable ranges may be selected from between any of these values.
[0019] Preferably the heat treatment of the liquid source precipitates about 2, 3, 4, 5, 6, 7, 8, 9 or 10% of the minerals present in the liquid source, and suitable ranges may be selected from between any of these values.
[0020] Preferably the first permeate comprises
less than about 96% of the minerals in the liquid source, and/or
less than about 20% of the protein in the liquid source.
[0021] Preferably the first retentate comprises
at least about 3% of the minerals in the liquid source, and/or
at least about 80% of the protein in the liquid source.
[0022] Preferably the filtration step results in a reduction in the amount of insoluble minerals and protein in the first permeate, when compared to the liquid source.
[0023] Preferably the filtration step of (b)(i) is carried out at about 50, 55, 60, 65, 70, 75, 80, 85 or 90°C to produce a first retentate and first permeate, and suitable ranges may be selected from between any of these values.
[0024] Preferably the heat resistant filter of (b)(i) is a ceramic filter.
[0025] Preferably the filtration step of (b)(ii) is carried out at about 55, 60, 65, or about 70°C to produce a first retentate and first permeate, and suitable ranges may be selected from between any of these values..
[0026] Preferably the filtration step of (b)(ii) is carried out using a heat resistant filter. [0027] Preferably the heat resistant filter of (b)(ii) is a ceramic filter.
[0028] Preferably the heat treated liquid source is subjected to ultrafiltration with a ceramic filter.
[0029] Preferably the ceramic ultrafiltration is conducted at a temperature of from about 50, 55, 60, 65, 70, 75, 80, 85 or 90°C, and suitable ranges may be selected from between any of these values. Preferably the ceramic ultrafiltration is conducted at a temperature of from about 60°C to about 80°C.
[0030] Preferably at least one glycoside hydrolase or polymerase enzyme reaction.
[0031] Preferably
a) the first permeate,
b) the light phase,
c) the concentrated second retentate, or
d) a combination of any two or more of (a) to (c),
is subjected to the enzyme reaction.
[0032] Preferably the enzyme reaction
a) increases the molecular size of at least one disaccharide in the source to produce at least one oligosaccharide, or
b) decreases the molecular size of at least one disaccharide in the source to produce one or more monosaccharides.
[0033] Preferably the enzyme comprises β-galactosidase.
[0034] Preferably the disaccharide comprises lactose.
[0035] Preferably the monosaccharide comprises galactose or glucose.
[0036] Preferably the oligosaccharide comprises one or more
galactooligosaccharides.
[0037] Preferably the filtration of the light phase is ultrafiltration.
[0038] Preferably the ultrafiltration is conducted at a temperature of from about 50, 55, 60, 65 or 70 °C, and suitable ranges may be selected from between any of these values. Preferably the ultrafiltration is conducted at a temperature of from about 55 °C to about 65 °C.
[0039] Preferably the nanofiltration is conducted at a temperature of from about 25, 30, 35, 40, 45, 50 or 55 °C, and suitable ranges may be selected from between any of these values. Preferably the ultrafiltration is conducted at a temperature of about 50 °C.
[0040] Preferably the second permeate comprises soluble minerals and at least one monosaccharide or disaccharide.
[0041] Preferably the second retentate comprises
less than about 70% of the minerals in the first permeate, or
less than about 50% of the non-sialyloligosaccharide sugars in the first permeate.
[0042] Preferably the second retentate comprises
at least about 7% by weight sialyloligosaccharides,
at least about 0.2% by weight neutral oligosaccharides, less than about 5% by weight protein and non-protein nitrogen, less than about 80% by weight non-sialyloligosaccharide sugars, and less than about 5% by weight ash.
[0043] Preferably the second permeate comprises
at least about 30% of the minerals in the first permeate, or
at least about 50% of the non-sialyloligosaccharide sugars in the first permeate.
[0044] Preferably the second retentate is subjected to either nanofiltration or reverse osmosis to produce a third retentate.
[0045] Preferably the concentrated second retentate, or the third retentate, is subjected to decolourisation.
[0046] Preferably the method comprises the steps of
subjecting the sialyloligosaccharide-containing extract to crystallisation to produce a crystallised sialyloligosaccharide-containing extract, and drying the sialyloligosaccharide-containing extract or crystallised
sialyloligosaccharide-containing extract to produce a dried sialyloligosaccharide- containing extract.
[0047] Preferably the sialyloligosaccharide-containing extract comprises less than about 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4 3, 2, or 1% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values.
[0048] Preferably the sialyloligosaccharide-containing extract comprises less than about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% by weight ash, and suitable ranges may be selected from between any of these values.
[0049] Preferably the sialyloligosaccharide-containing extract comprises, on a dry solids basis
at least about 7% by weight sialyloligosaccharides,
at least about 0.2% by weight neutral oligosaccharides, less than about 5% by weight protein and non-protein nitrogen, less than about 80% by weight non-sialyloligosaccharide sugars, and less than about 5% by weight ash.
[0050] Preferably the sialyloligosaccharide-containing extract comprises, on a dry solids basis
at least about 5% by weight 3'-sialyllactose, and
at least about 2% by weight 6'-sialyllactose.
[0051] In a further aspect the invention relates to a sialyloligosaccharide- containing extract produced by any one of the methods described above.
[0052] Preferably the composition comprises, on a dry solids basis, a greater amount of 3'-sialyllactose relative to the amount of 6'-sialyllactose.
[0053] Preferably the composition comprises 3'-sialyllactose and 6'- sialyllactose in a ratio of from about 65: 1 to about 1.5: 1, from about 15 : 1 to about 1.5 : 1, or from about 8 : 1 to about 1.5 : 1, and suitable ranges may be selected from between any of these values.
[0054] In a further aspect the invention relates to a nutritional formulation comprising a sialyloligosaccharide-containing extract produced by a method as described above, or comprises a sialyloligosaccharide-enriched composition as described above.
[0055] Preferably the nutritional formulation is an infant formula, a follow-on formula, a growing-up formula, a paediatric formula, a human milk fortifier, a children's food or drink, a maternal supplement, a maternal nutritional formulation, a fermented food, a UHT milk, a UHT drinking yoghurt, an acidified milk drink, a UHT powder, a medical food, a sports nutritional formulation, or a formulation for senior or aged populations.
[0056] Preferably the nutritional formulation comprises one or more dairy lipids, one or more galactooligosaccharides, one or more probiotic strains, one or more protein hydrolysates, lactoferrin, a milk fat globular membrane (MFGM) formulation, other prebiotics, or a combination of any two or more thereof.
[0057] Preferably the nutritional formulation the dairy lipid comprises buttermilk, high fat whey protein concentrate, beta-serum, butter serum, or a combination of any two or more thereof.
[0058] Preferably the probiotic strain comprises a Bifidobacterium lactis or a Lactobacillus rhamnosus strain, or a combination of both Bifidobacterium lactis and Lactobacillus rhamnosus.
[0059] Preferably the Bifidobacterium lactis strain comprises Bifidobacterium lactis HN019 (DR10™).
[0060] Preferably the Lactobacillus rhamnosus strain comprises Lactobacillus rhamnosus HN001 (DR20™).
[0061] In a further aspect the invention relates to a method of maintaining or increasing brain function or brain development, the method comprising
administering (i) an effective amount of a sialyloligosaccharide-containing extract produced by the method as described above, or (ii) a nutritional formulation as described above, to a normal subject.
[0062] Preferably the sialyloligosaccharide-containing extract comprises
a) one or more structural glycoconjugates of sialic acid,
b) free sialic acid, or
c) both (a) and (b). [0063] Preferably the extract, composition or nutritional formulation is administered to
a) prevent delayed brain development,
b) maintain the viability or function of neuronal cells,
c) maintain or increase cognitive development,
d) prevent delayed cognitive development,
e) maintain or increase cognitive performance,
f) prevent cognitive decline,
g) maintain or increase learning, memory or attention span,
h) prevent decline of learning ability, memory or attention span, i) maintain or increase ability to cope with stress,
j) maintain or increase the level of neural cell adhesion molecule
(NCAM),
k) prevent decline in brain function,
I) maintain or increase the level of gangliosides in the brain, m) maintain or increase blood, nutrient or oxygen flow to the brain, n) maintain or increase synaptogenesis,
o) maintain or increase the activity of the gut/brain axis,
p) maintain or increase neurogenesis in an older brain,
q) maintain or increase white matter volume, or
r) a combination of any two or more of a) to q).
[0064] Preferably the subject is a foetal, infant or child subject.
[0065] Preferably the extract, composition or nutritional formulation is administered to a mother during gestation to maintain or increase brain function or development in a foetal subject.
[0066] Preferably the extract, composition or formulation is administered to a breastfeeding mother to maintain or increase brain function or development in an infant subject.
[0067] In one embodiment the administration of the composition of the invention to an individual leads to an increase in glycerophosphorylcholine (GPC) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values. [0068] In one embodiment the administration of the composition of the invention to an individual leads to an increase in glutamine (Glu) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0069] In one embodiment the administration of the composition of the invention to an individual leads to an increase in myo inositol (Ins) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0070] In one embodiment the administration of the composition of the invention to an individual leads to a decrease in Lip09 in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0071] In one embodiment the administration of the composition of the invention to an individual leads to a decrease in macromolecules (MM) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0072] In one embodiment the administration of the composition of the invention to an individual leads to an increase in N-Acetylaspartylglutamic acid (NAAG) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0073] In one embodiment the administration of the composition of the invention to an individual leads to an increase in the glutamate-glutamine complex (Glx) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0074] In a further aspect the invention relates to a method of treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age- related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia comprising administering an effective amount of a sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 32, an extract or composition of any one of claims 33 to 36 or 44 to 46, or a nutritional formulation of any one of claims 37 to 43 to a subject in need thereof.
[0075] In a further aspect the invention relates to a sialyloligosaccharide- containing extract produced by a method of any one of claims 1 to 32, a
composition of any one of claims 33 to 38 or 44 to 46, or a nutritional formulation of any one of claims 37 to 43 for treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia.
[0076] In a further aspect the invention relates to a the use of a
sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 32, or a composition of any one of claims 33 to 36 or 44 to 46, in the manufacture of a formulation for treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia.
[0077] It is intended that reference to a range of numbers disclosed herein (for example, 1 to 10) also incorporates reference to all rational numbers within that range (for example, 1, 1.1, 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9 and 10) and also any range of rational numbers within that range (for example, 2 to 8, 1.5 to 5.5 and 3.1 to 4.7).
[0078] This invention may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, and any or all combinations of any two or more of said parts, elements or features, and where specific integers are mentioned herein which have known equivalents in the art to which this invention relates, such known equivalents are deemed to be incorporated herein as if individually set forth.
[0079] In this specification, where reference has been made to external sources of information, including patent specifications and other documents, this is generally for the purpose of providing a context for discussing the features of the present invention. Unless stated otherwise, reference to such sources of
information is not to be construed, in any jurisdiction, as an admission that such sources of information are prior art or form part of the common general knowledge in the art.
[0080] The term "comprising" as used in this specification means "consisting at least in part of". When interpreting statements in this specification which include that term, the features, prefaced by that term in each statement, all need to be present but other features can also be present. Related terms such as "comprise" and "comprised" are to be interpreted in the same manner. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The invention will now be described by way of example only and with reference to the drawings in which :
[0082] Figure 1 shows a process flow diagram of the method for producing a sialyloligosaccharide-containing extract.
[0083] Figure 2 shows a graph reporting the results of discrimination tests using a 3 hour "easy" task using an 8-arm radial maze.
[0084] Figure 3 shows a graph reporting the results of discrimination tests using a 3 hour "more difficult" task using an 8-arm radial maze.
[0085] Figure 4 shows a graph reporting the results of learning ability on a difficulty tasks using a learning criteria of a maximum of one mistake within four consecutive trials.
[0086] Figure 5 shows a graph reporting PolySia expression in the frontal cortex in two treatment group compared with control.
DETAILED DESCRIPTION OF THE INVENTION
[0087] The present invention relates to a method for the production of sialyloligosaccharide-enriched extracts for use in nutritional formulations including infant formulas.
[0088] The present invention also provides sialyloligosaccharide-enriched compositions, nutritional formulations comprising such compositions and uses of the compositions and nutritional formulations.
[0089] The various embodiments of the composition and methods of the invention have numerous advantages, including but not limited to the production of a high concentration sialyloligosaccharide composition that is low in impurities.
1. Source material
[0090] The sialyloligosaccharide-containing liquid source for use in the invention is obtained from mammalian milk. It should be appreciated that any fraction or milk derivative can be utilised in the invention provided it contains
sialyloligosaccharides. [0091] In some embodiments, the sialyloligosaccharide-containing liquid source is derived from any mammalian milk including but not limited to bovine, sheep, goat, pig, mouse, water buffalo, camel, yak, horse, donkey, llama or human milk fat, with bovine milk being a preferred source.
[0092] In some embodiments the mammalian milk source is processed to remove at least protein and fat prior to being used in the inventive process.
[0093] By way of example, the sialyloligosaccharide-containing source may be generated from upstream milk processes, such as cheese manufacture or casein manufacture that produce a permeate. Examples of upstream milk processes include the production of cheese whey, rennet (sweet) whey, or ultrafiltration of skim or raw milk. After ultrafiltration of whey protein the protein is retained in the whey retentate and the whey permeate contains sialyloligosaccharides, lactose and minerals, since sialyloligosaccharides, lactose and minerals pass though the ultrafiltration membrane.
[0094] The sialyloligosaccharide-containing liquid source (e.g. permeate from upstream dairy processing) may then be processed by one or more filtration steps and may include one or more concentration steps.
[0095] In some embodiments the sialyloligosaccharide-containing liquid source comprises the permeate resulting from filtration of whole milk, recombined, powdered or fresh skim milk, recombined or reconstituted whole or skim milk powder, skim milk concentrate, skim milk retentate, concentrated milk, ultrafiltered milk retentate, colostrum, whey (including sweet whey, lactic acid whey, mineral acid whey, reconstituted whey powder or deproteinated whey), a composition derived from any milk processing stream, a composition derived from the permeate obtained by ultrafiltration or microfiltration of any milk processing stream, or a combination of any two or more thereof.
[0096] In one embodiment, the sialyloligosaccharide-containing liquid source comprises the permeate from upstream dairy processing processed by one or more filtration steps and/or concentration steps. In one embodiment, the
sialyloligosaccharide-containing liquid source comprises the mother liquor produced as a by-product of lactose crystallisation. Following lactose crystallisation, the crystallised lactose is separated from the remaining solution. The remaining solution, the mother liquor (also known as delactosed permeate or Delac), comprises lactose, sialyloligosaccharides and minerals.
[0097] In one embodiment the sialyloligosaccharide-containing liquid source comprises one or more sialyloligosaccharide-containing streams.
[0098] In various embodiments the sialyloligosaccharide-containing liquid source comprises the mother liquor of lactose crystallisation (delactosed permeate), a dairy permeate, whey, whey permeate, or a combination of any two or more thereof.
[0099] In various embodiments the sialyloligosaccharide-containing liquid source comprises at least about 0.2, 0.5, 1, 2, 4, 6, 8, 10 or 12% by weight sialyloligosaccharides, and suitable ranges may be selected from between any of these values, (for example, about 0.2 to about 12, about 0.2 to about 8, about 0.2 to about 6, about 0.2 to about 4, about 0.5 to about 12, about 0.5 to about 10, about 0.5 to about 6, about 0.5 to about 2, about 1 to about 12, about 1 to about 10, about 1 to about 4, about 2 to about 12, about 2 to about 8, about 2 to about 6, about 4 to about 12, about 4 to about 10, about 4 to about 6, about 6 to about 12, about 6 to about 10 or about 8 to about 12% by weight sialyloligosaccharides).
[OIOO] In various embodiments the sialyloligosaccharide-containing liquid source comprises less than about 0.01, 0.05, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2 or 2.25% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values, (for example, from about 0.01 to about 2.25, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 0.5, about 0.01 to about 0.3, about 0.01 to about 0.2, about 0.05 to about 2.25, about 0.05 to about 2, about 0.05 to about 1.5, about 0.05 to about 0.75, about 0.05 to about 0.4, about 0.05 to about 0.25, about 0.1 to about 2.25, about 0.1 to about 1.75, about 0.1 to about 1.25, about 0.1 to about 0.75, about 0.1 to about 0.5, about 0.2 to about 2.25, about 0.2 to about 2, about 0.2 to about 0.75, about 0.2 to about 0.5, about 0.25 to about 2.25, about 0.25 to about 2, about 0.25 to about 1.5, about 0.25 to about 1.25, about 0.25 to about 1, about 0.25 to about 0.75, about 0.3 to about 2.25, about 0.3 to about 2, about 0.3 to about 1.5, about 0.3 to about 1, about 0.3 to about 0.75, about 0.4 to about 2.25, about 0.4 to about 2, about 0.4 to about 1, about 0.4 to about 0.75, about 0.5 to about 2.25, about 0.5 to about 2, about 0.5 to about 1.75, about 0.5 to about 1, about 0.75 to about 2.25, about 0.75 to about 2, about 0.75 to about 1.5, about 1 to about 2.25, about 1 to about 1.75, about 1 to about 1.5, about 1.25 to about 2.25, about 1.25 to about 1.75, about 1.25 to about 1.5, about 1.5 to about 2.25, about 1.5 to about 2 or about 1.75 to about 2.25% by weight protein)
[0101] In various embodiments the sialyloligosaccharide-containing liquid source comprises less than about 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or at least about 75% by weight non-sialyloligosaccharide sugars, and suitable ranges may be selected from between any of these values, (for example, from about 10 to about 75, about 10 to about 70, about 10 to about 65, about 10 to about 60, about 20 to about 75, about 20 to about 70, about 20 to about 65, about 20 to about 60, about 30 to about 75, about 30 to about 70, about 30 to about 65, about 30 to about 60, about 40 to about 75, about 40 to about 70, about 40 to about 65, or about 40 to about 60% by weight non-sialyloligosaccharide sugars).
[0102] In various embodiments the sialyloligosaccharide-containing liquid source comprises 3'-sialyllactose and 6'-sialyllactose in a ratio of about 65:1, 50:1, 40:1, 30:1, 25:1, 20:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1 or 1.5:1 and suitable ranges may be selected from between any of these values, (for example, from about 65: 1 to about 1.5:1, about 65: 1 to about 1.5:1, about 65:1 to about 3:1, about 65:1 to about 7:1, about 65:1 to about 9:1, about 65:1 to about 13:1, about 65:1 to about 15:1, about 65:1 to about 20:1, about 50:1 to about 1.5:1, about 50:1 to about 1.5:1, about 50:1 to about 3:1, about 50: 1 to about 7:1, about 50: 1 to about 9:1, about 50: 1 to about 13:1, about 50:1 to about 15:1, about 50:1 to about 20:1, about 40:1 to about 1.5:1, about 40:1 to about 1.5:1, about 40:1 to about 3:1, 40:1 to about 7:1, about 40:1 to about 9:1, about 40:1 to about 13:1, about 40:1 to about 15:1, about 40:1 to about 20:1, about 30:1 to about 1.5:1, about 30:1 to about 1.5:1, about 30:1 to about 3:1, about 30: 1 to about 7:1, about 30: 1 to about 9:1, about 30: 1 to about 13:1, about 30:1 to about 15:1, about 30:1 to about 20:1, about 25:1 to about 1.5:1, about 25:1 to about 1.5:1, about 25:1 to about 4:1, about 25:1 to about 8:1, about 25:1 to about 10:1, about 25:1 to about 12:1, about 25:1 to about 14:1, about 25:1 to about 20:1, about 20:1 to about 1.5:1, about 20:1 to about 1.5:1, about 20:1 to about 3:1, about 20:1 to about 8:1, about 20:1 to about 11:1, 20:1 to about 15:1, 15:1 to about 1.5:1, about 15:1 to about 1.5:1, about 15:1 to about 2:1, about 12:1 to about 1.5:1, about 12:1 to about 1.5:1, about 12:1 to about 2:1, about 10:1 to about 1.5:1, about 10:1 to about 1.5:1, about 10:1 to about 2:1, about 8:1 to about 1.5:1, about 8:1 to about 1.5:1, about 18:1 to about 2:1, about 7:1 to about 1.5:1, about 7:1 to about 1.5:1, about 7:1 to about 2:1, about 6:1 to about 1.5:1, about 6:1 to about 1.5:1, about 6:1 to about 2:1, about 5:1 to about 1.5:1, from about 15:1 to about 1:1, about 12:1 to about 1:1, about 10:1 to about 1:1, about 8:1 to about 1:1, about 7:1 to about 1:1, about 6:1 to about 1:1, about 5:1 to about 1:1, about 15:1 to about 2:1, about 12:1 to about 2:1, about 10:1 to about 2:1, about 8:1 to about 2:1, about 7:1 to about 2:1, about 6:1 to about 2:1, about 5:1 to about 2:1, about 15:1 to about 3:1, about 12:1 to about 3:1, about 10:1 to about 3:1, about 8:1 to about 3:1, about 7:1 to about 3:1, about 6:1 to about 3:1, or about 5: 1 to about 3:1.
[0103] In those embodiments where the sialyloligosaccharide-containing liquid source is a mother liqueur then the ratio of 3'-sialyllactose and 6'-sialyllactose is about 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1.5:1 or 1.5:1 and suitable ranges may be selected from between any of these values, (for example, from about 15:1 to about 1.5:1, about 12:1 to about 1.5:1, about 10:1 to about 1.5:1, about 8:1 to about 1.5:1, about 7:1 to about 1.5:1, about 6:1 to about 1.5:1, about 5:1 to about 1.5:1, from about 15:1 to about 1:1, about 12:1 to about 1:1, about 10:1 to about 1:1, about 8:1 to about 1:1, about 7:1 to about 1:1, about 6:1 to about 1:1, about 5:1 to about 1:1, about 15:1 to about 2:1, about 12:1 to about 2:1, about 10:1 to about 2:1, about 8:1 to about 2:1, about 7:1 to about 2:1, about 6:1 to about 2:1, about 5:1 to about 2:1, about 15:1 to about 3:1, about 12:1 to about 3:1, about 10:1 to about 3:1, about 8:1 to about 3:1, about 7: 1 to about 3:1, about 6: 1 to about 3:1, or about 5: 1 to about 3:1).
2. Removal of insoluble minerals and protein
[0104] The first step of the method removes at least insoluble minerals and protein from the sialyloligosaccharide-containing source. In some embodiments the first step also removes fat from the sialyloligosaccharide-containing source.
[0105] In one embodiment the sialyloligosaccharide-containing liquid source is heated to a temperature of at least about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, or at least about 75°C to precipitate minerals in the source. The temperature may be controlled during this step by injection of steam or water, or both steam and water. [0106] In some embodiments the sialyloligosaccharide-containing liquid source is heated for a period of at least about 30, 60 or 90 seconds, or at least about 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes. Preferably the heating step is carried out for about 5 min.
[0107] In some embodiments the heat treatment of the liquid source precipitates about 2, 3, 4, 5, 6, 7, 8, 9 or 10% of the minerals present in the liquid source, and suitable ranges may be selected from between any of these values, (for example, about 2 to about 10, about 2 to about 8, about 2 to about 6, about 3 to about 10, about 3 to about 9, about 3 to about 8, about 3 to about 6, about 4 to about 10, about 4 to about 8, about 4 to about 6%).
[0108] In various embodiments the sialyloligosaccharide-containing liquid source is subjected to a demineralisation step to remove insoluble minerals from the source.
[0109] In one embodiment the insoluble minerals, including any precipitated minerals produced by heating, are removed by centrifugation. Other suitable methods for removing insoluble minerals may be used as will be readily apparent to those skilled in the art.
[0110] In some embodiments the demineralisation step also removes protein from the sialyloligosaccharide-containing liquid source.
[0111] In some embodiments the demineralised liquid source is concentrated using any of the methods described below.
[0112] In some embodiments, filtration is used to remove at least protein. In other embodiments filtration is used to remove at least insoluble minerals and protein.
Ceramic filtration
[0113] In various embodiments ceramic filtration is used to remove insoluble minerals and protein from the sialyloligosaccharide-containing liquid source.
Ceramic filtration separates the protein and insoluble minerals retained in the filtration retentate from the lactose, oligosaccharides and soluble minerals contained in the filtration permeate. [0114] In one embodiment the sialyloligosaccharide-containing liquid source is heated to precipitate minerals in the source as described above before ceramic filtration is performed at a temperature of about 35 to about 95°C.
[0115] In one embodiment the sialyloligosaccharide-containing liquid source is heated to precipitate minerals in the source as described above, followed by centrifugation and then ceramic filtration light phase at a temperature of about 50 to about 70°C is performed.
[0116] In one exemplary embodiment the method comprises ceramic ultrafiltration.
[0117] In various embodiments the method comprises ceramic filtration using a ceramic membrane comprising aluminium oxide or zirconium oxide.
[0118] In various embodiments the ceramic filtration is conducted using a membrane having a molecular weight cutoff of at least about 500, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,250, 1,300, 1,400, 1,500, 1,750, 2,000, 2,500, 5,000, 10,000, 15,000, 20,000, 25,000, 30,000, 50,000, 100,000, 150,000 or 200,000 Da and useful ranges may be selected from between any of these values, (for example, from about 500 to about 200,000, about 500 to about 100,000, about 500 to about 30,000, about 500 to about 10,000, about 500 to about 5,000, about 500 to about 2,500, about 500 to about 2,000, about 500 to about 1,500, from about 750 to about 200,000, about 750 to about 100,000, 750 to about 30,000, about 750 to about 10,000, about 750 to about 5,000, about 750 to about 2,500, about 750 to about 2,000, about 750 to about 1,500, from about 1,000 to about 200,000, about 1,000 to about 100,000, about 1,000 to about 30,000, about 1,000 to about 10,000, about 1,000 to about 5,000, about 1,000 to about 2,500, about 1,000 to about 2,000, or about 1,000 to about 1,500 Da).
[0119] In various embodiments the ceramic filtration is conducted using a membrane having a pore size of at least about 0.001, 0.005, 0.01, 0.05, 0.1, 0.25, 0.4, 0.5, 0.6, 0.75, 0.8, 1, 1.25, 1.4, 1.5, 1.6, 1.75, 1.8, 2, 2.5 or 3 μηη and useful ranges may be selected from between any of these values, (for example, from about 0.001 to about 3, about 0.001 to about 2.5, about 0.001 to about 2, 0.001 to about 1.75, 0.001 to about 1.5, about 0.005 to about 3, about 0.005 to about 2.5, about 0.005 to about 2, 0.005 to about 1.75, 0.005 to about 1.5, about 0.01 to about 3, about 0.01 to about 2.5, about 0.01 to about 2, 0.01 to about 1.75, or from about 0.01 to about 1.5 μηι).
[0120] In various embodiments ceramic filtration is conducted at a temperature of at least about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95°C, and useful ranges may be selected from between any of these values, (for example, from about 30 to about 95, about 40 to about 95, about 50 to about 95, about 40 to about 90, about 50 to about 90, about 60 to about 90, about 65 to about 90, about 40 to about 85, about 50 to about 85, about 55 to about 85, about 60 to about 90, about 65 to about 90, about 40 to about 80, about 50 to about 80, about 55 to about 80, about 60 to about 80, about 65 to about 80, about 40 to about 75, about 50 to about 75, about 55 to about 75, about 60 to about 75, or about 65 to about 75°C).
[0121] In various embodiments ceramic filtration is conducted at a pressure of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 bar, and useful ranges may be selected from between any of these values, (for example, from about 1 to about 15, about 2 to about 15, about 3 to about 15, about 1 to about 12, about 3 to about 12, about 1 to about 10, about 3 to about 10, about 1 to about 8, about 2 to about 8, about 3 to about 8, about 1 to about 7, about 2 to about 7, about 3 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 1 to about 5, about 2 to about 5, or about 3 to about 5 bar) .
[0122] In one embodiment the method comprises ceramic filtration in combination with diafiltration.
Other filtration methods
[0123] In various embodiments ultrafiltration or nanofiltration is used to remove at least protein. Filtration may be used to separate the protein, which is retained in the filtration retentate, from saccharides such as lactose and soluble minerals contained in the filtration permeate.
[0124] In some embodiments ultrafiltration or nanofiltration is used in combination with diafiltration.
[0125] Surprisingly, it has been found that ultrafiltration performed at high temperature leads to an improved yield in downstream processing steps, for example, an improved sialyloligosaccharide yield in the nanofiltration retentate and the final sialyloligosaccharide-containing extract. Increasing UF temperature from about 10°C to about 50°C increases sialyloligosaccharide yield by about 100% in the process. Increasing UF temperature from about 10°C to about 65°C increases sialyloligosaccharide yield by about 130%. Increasing UF temperature above about 65°C will increase sialyloligosaccharide yield but in smaller increments than if increased up to 65°C.
[0126] In various embodiments ultrafiltration is conducted at a temperature of at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or 90°C, and useful ranges may be selected from between any of these values, (for example, from about 25 to about 90, about 40 to about 90, about 50 to about 90, about 30 to about 85, about 40 to about 85, about 50 to about 85, about 55 to about 85, about 30 to about 80, about 40 to about 80, about 50 to about 80, about 55 to about 80, about 30 to about 75, about 40 to about 75, about 50 to about 75, about 55 to about 75, about 30 to about 70, about 40 to about 70, about 50 to about 70, about 55 to about 70, about 30 to about 65, about 65 to about 75, about 50 to about 65, or about 55 to about 65°C).
[0127] Suitable membranes for ultrafiltration include polyethersulfone membranes. Other ultrafiltration membranes known in the art may also be suitable as will be apparent to those skilled in the art.
[0128] In various embodiments ultrafiltration is conducted using a membrane having a molecular weight cutoff of at least about 1,000, 1,500, 2,000, 3,000, 3,500, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 12,500, 15,000, 17,500, 20,000, 25,000 or 30,000 Da, and useful ranges may be selected from between any of these values, for example, (from about 1,000 to about 30,000, about 3,000 to about 30,000, about 5,000 to about 30,000, about 1,000 to about 25,000, about 2,000 to about 25,000, about 3,000 to about 25,000, about 5,000 to about 25,000, about 1,000 to about 20,000, about 2,000 to about 20,000, about 3,000 to about 20,000, about 5,000 to about 20,000, about 10,000 to about 20,000, about 2,000 to about 15,000, about 3,000 to about 15,000, about 5,000 to about 15,000, about 2,000 to about 10,000, about 3,000 to about 10,000, or about 5,000 to about 10,000 Da).
[0129] In various embodiments ultrafiltration is conducted at a pressure of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 bar, and useful ranges may be selected from between any of these values, (for example, from about 1 to about 15, about 2 to about 15, about 3 to about 15, about 4 to about 15, about 5 to about 15, about 1 to about 12, about 2 to about 10, about 3 to about 10, about 4 to about 10, about 5 to about 10, about 1 to about 8, about 2 to about 8, about 3 to about 8, about 4 to about 8, about 5 to about 8, about 1 to about 7, about 2 to about 7, about 3 to about 7, about 4 to about 7, about 5 to about 7, about 1 to about 6, about 2 to about 6, about 3 to about 6, about 4 to about 6, about 5 to about 6, about 1 to about 5, about 2 to about 5, about 3 to about 5 or about 4 to about 5 bar).
[0130] In various embodiments nanofiltration is conducted using a
membrane having a molecular weight cutoff of at least about 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 kDa, and useful ranges may be selected from between any of these values, (for example, about 0.1 to about 1, about 0.1 to about 0.8, about 0.1 to about 0.5, about 0.1 to about 0.4, about 0.1 to about 0.3, about 0.1 to about 0.25, about 0.1 to about 0.2, about 0.2 to about 1, about 0.2 to about 0.6, about 0.2 to about 0.5, about 0.2 to about 0.3, about 0.2 to about 0.25, about 0.3 to about 1, about 0.3 to about 0.8, about 0.3 to about 0.6, about 0.3 to about 0.5, about 0.4 to about 1, about 0.4 to about 0.6, about 0.5 to about 1, about 0.5 to about 0.8, about 0.6 to about 1, about 0.6 to about 0.7, about 0.7 to about 1 kDa).
[0131] In various embodiments nanofiltration is conducted at a temperature of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75°C, and useful ranges may be selected from between any of these values, (for example, from about 15 to about 75, about 20 to about 75, about 25 to about 75, about 15 to about 70, about 20 to about 70, about 25 to about 70, about 15 to about 65, about 20 to about 65, about 25 to about 65, about 15 to about 60, about 20 to about 60, about 25 to about 60, about 15 to about 55, about 20 to about 55, or about 25 to about 55°C).
[0132] Suitable membranes for nanofiltration include polyamide-imide membranes or polyamide thin film composite membranes. Suitable polyamide- imide membranes include the Synder® NF membranes, including the Synder® NFS, NFX and NFW membranes. Other nanofiltration membranes known in the art may also be suitable as will be apparent to those skilled in the art.
[0133] In various embodiments nanofiltration is conducted using a
membrane having a molecular weight cutoff of at least about 10, 25, 50, 100, 150, 200, 250, 300, 350, 400 or at least about 500 Da, and useful ranges may be selected from between any of these values, (for example, from about 10 to about 500, about 50 to about 500, about 100 to about 500, about 10 to about 400, about 50 to about 400, about 100 to about 400, about 10 to about 300, about 50 to about 300, about 100 to about 300, about 10 to about 250, about 50 to about 250, or about 100 to about 250 Da).
[0134] In various embodiments nanofiltration is conducted at a pressure of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or at least about 75 bar, and useful ranges may be selected from between any of these values, (for example, from about 5 to about 75, about 30 to about 75, about 35 to about 75, about 5 to about 70, about 30 to about 70, about 35 to about 70, about 5 to about 65, about 30 to about 65, about 35 to about 65, about 5 to about 60, about 25 to about 60, about 30 to about 60, about 35 to about 60, about 40 to about 60, about 5 to about 55, about 25 to about 55, about 30 to about 55, about 35 to about 55, about 40 to about 55, about 5 to about 50, about 25 to about 50, about 30 to about 50, about 35 to about 50, about 40 to about 50, about 5 to about 45, about 25 to about 45, about 30 to about 45, about 35 to about 45, or about 40 to about 45 bar).
3. Disaccharide removal
[0135] Various methods may be used to separate disaccharides, particularly lactose, from sialyloligosaccharides in the sialyloligosaccharide-containing source material.
3.1 Enzyme reaction
[0136] In some embodiments the method comprises an enzyme reaction to increase or decrease the molecular size of one or more disaccharides to produce one or more monosaccharides or oligosaccharides.
[0137] The reaction product may be subjected to filtration to remove the monosaccharides or oligosaccharides produced by the enzyme reaction. Methods to measure oligosaccharides such as galactooligosaccharides are given by "AOAC official method of 2001. 02 trans-Galactooligosaccharides (TGOS)," in Selected Food Products, AOAC International, Gaithersburg, Md, USA, 2005." Any suitable method designed for this purpose could also be used. Suitable filtration conditions are discussed above. Filtration conditions, for example, membrane pore size or molecular weight cutoff, temperature and pressure, are selected such that the monosaccharides or polysaccharides to be removed are retained in the retentate and the sialyloligosaccharides are contained in the permeate, or vice versa.
Methods to measure sialyloligosaccharides' are given by Fong, B. et al., 2011.
Quantification of bovine milk oligosaccharides using liquid chromatography-selected reaction monitoring-mass spectrometry. Journal of agricultural and food chemistry, 59(18), pp.9788-9795.
[0138] In one embodiment the enzyme reaction increases the molecular size of the disaccharide to produce one or more polysaccharides. In another
embodiment the enzyme reaction decreases the molecular size of the disaccharide to produce one or more monosaccharides.
[0139] In one embodiment the enzyme is a β-galactosidase. β-galactosidase catalyses the hydrolysis of the β-glycosidic bond between galactose and other sugars. The conditions of the enzyme reaction may be manipulated to produce monosaccharides and/or oligosaccharides.
[0140] The β-galactosidase can be sourced from Kluyveromyces fragilis, Aspergillus niger, Aspergillus oryzae, Kluyveromyces lactis, Kluyveromyces spp., Penicillium spp., Rhodotorula spp., Sporobolomyces singularis, Bifidobacterium spp., Bacillus spp., Bacillus circulans, Escherichia coli, Lactobacillus thermophiles,
Lactobacillus spp., Leuconostoc, citrovorum or Enterobacter spp.
[0141] For example, when there is an excess of disaccharide available, transglycosylation to produce oligosaccharides may be favoured. It may be necessary to perform a concentration step before an enzyme reaction to promote transglycosylation.
[0142] In various embodiments the input material (first permeate or deminerliased liquid source) to increase the molecular size of at least one disaccharide comprises at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% or at least about 70% disaccharides, particularly lactose. Suitable ranges may be selected from between any of these values, for example, from about 30% to about 70% or from about 40% to about 60%.
[0143] When there is limited disaccharide available, hydrolysis to produce monosaccharides may be favoured. In various embodiments the input material (first permeate or demineralised liquid source) to an enzyme reaction to decrease the molecular size of at least one disaccharide comprises at least about 5, 10, 15, 20, 25, 30, 35, or 40% by weight disaccharides, particularly lactose. Suitable ranges may be selected from between any of these values, for example, from about 5 to about 40 or from about 20 to about 30% by weight.
[0144] For the hydrolysis reaction, we conducted this reaction on milk permeate at 3 pH values: 6.1, 6.3, and 6.5 and at 40°C. A single enzyme addition rate was used (36735 NLU/kg of lactose). The enzyme was GODO-YLN2 from Danisco. The reaction was also undertaken on lactose mother liquor (lactose concentration of 42% w/w) at a pH of 4.28, and at two temperatures (54 and 58.5°C). The enzyme used was 17MDP from Biocatalysts (UK). Our selection of conditions were similar to the recommended ones, but process conditions were modified to suit the enzyme. No significant variations in results were found across the different parameters tested.
[0145] In one exemplary embodiment β-galactosidase catalyses the production of galactooligosaccharides (GOS) from lactose. The reaction product may be subjected to nanofiltration to remove the GOS. In one embodiment nanofiltration is used to remove GOS and protein.
[0146] In another exemplary embodiment β-galactosidase catalyses the production of galactose and glucose from lactose. The reaction product may be subjected to nanofiltration to remove the galactose and glucose. In one embodiment nanofiltration removes galactose, glucose and soluble minerals.
[0147] In various embodiments two or more enzyme reaction steps are conducted.
[0148] For example, in one embodiment a first enzyme reaction step is conducted to produce one or more monosaccharides. A second enzyme step is conducted to produce one or more oligosaccharides.
[0149] In one embodiment the first enzyme reaction step is conducted after ceramic filtration. In another embodiment the first enzyme reaction step is conducted after demineralisation, prior to ultrafiltration.
[0150] In one embodiment the second enzyme reaction step is conducted after nanofiltration and before concentration. 4. Concentration
[0151] In various embodiments the method comprises one or more steps to concentrate the sialyloligosaccharides.
[0152] In some embodiments concentration is by removing water. Any concentration process can be used to effect this, such as nanofiltration, reverse osmosis or evaporation. Both reverse osmosis and evaporation may be used.
[0153] Evaporation for the purpose of concentration may be carried out by any suitable evaporative process. Evaporators such as a falling film evaporator, rising film evaporator, plate evaporator, or multiple effect evaporator may be used .
[0154] In some embodiments nanofiltration is used in combination with reverse osmosis.
[0155] In some embodiments, for example prior to an enzyme reaction to produce oligosaccharides, nanofiltration, reverse osmosis and evaporation are used
5. Decolourisation
[0156] In one embodiment the reaction product is subjected to
decolourisation to remove impurities that cause discolouration and/or undesirable odours. Decolourisation can be determined by measuring the change in absorbance with a spectrophotometer over the visible range of wavelengths.
[0157] In one embodiment decolourisation is performed by exposing the liquid stream to activated carbon. A subsequent filtration step is conducted to remove the activated carbon from the stream. Decolourisation may be conducted as a batch or continuous process.
[0158] In various embodiments decolourisation is conducted at a
temperature of at least about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or at least about 95°C, and useful ranges may be selected from between any of these values, (for example, from about 25 to about 95, about 40 to about 95, about 50 to about 95, or about 55 to about 95°C).
6. Crystallisation and drying
[0159] In various embodiments at least one concentration step is performed to produce the sialyloligosaccharide-containing extract. [0160] The sialyloligosacchande-containing extract may be dried using suitable methods known in the art. In one embodiment the extract is subjected to crystallisation before drying.
7. Sialyloligosaccharide-containing compositions and extracts
[0161] The extracts and compositions of the invention are enriched in sialyloligosacchandes and neutral oligosaccharides and are low in impurities such as lactose, protein and minerals.
[0162] Sialyloligosacchandes are oligosaccharides comprising at least one sialic acid moiety. Sialic acids are N- or O-substituted derivatives of neuraminic acid. Mammalian milk comprises both free sialyloligosacchandes and
sialyloligosacchandes bound to glycoproteins and/or glycolipids.
[0163] In various embodiments the composition contains free sialic acid.
[0164] In various embodiments the composition or extract comprises 3'- sialyllactose, 6'-sialyllactose, disialyllactose, sialyllactosamine or a combination of any two or more thereof. In an exemplary embodiment the composition or extract comprises 3'-sialyllactose, 6'-sialyllactose, disialyllactose and sialyllactosamine.
[0165] In various embodiments the extract or composition comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35 or 40% by weight sialyloligosacchandes as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40, about 10 to about 40, about 1 to 35, about 5 to about 35, about 7 to about 35, about 10 to about 35, about 1 to about 30, about 5 to about 30, about 7 to about 30, about 10 to about 30, about 1 to about 25, about 5 to about 25, about 7 to about 25, about 10 to about 25, about 1 to about 20, 5 to about 20, about 7 to about 20, about 10 to about 20, about 1 to about 15, about 5 to about 15, about 7 to about 15 or from about 10 to about 15% by weight sialyloligosacchandes).
[0166] In various embodiments the composition or extract comprises at least about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, 30, 35 or 40% by weight 3'-sialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 40, about 5 to about 40, about 7 to about 40, about 10 to about 40, about 1 to 35, about 5 to about 35, about 7 to about 35, about 10 to about 35, about 1 to about 30, about 5 to about 30, about 7 to about 30, about 10 to about 30, about 1 to about 25, about 5 to about 25, about 7 to about 25, about 10 to about 25, about 1 to about 20, 5 to about 20, about 7 to about 20, about 10 to about 20, about 1 to about 15, about 5 to about 15, about 7 to about 15 or from about 10 to about 15% by weight 3'-sialyllactose).
[0167] In various embodiments the composition or extract comprises at least about 0.1, 0.5, 0.75, 1, 1.25, 1.5, 1.75., 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, 15, 17 or 20% by weight 6'-sialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.1 to about 20, about 0.1 to about 15, about 0.1 to about 12, about 0.1 to about 10, about 0.1 to about 8, about 0.5 to about 20, about 0.5 to about 15, about 0.5 to about 12, about 0.5 to about 10, about 0.5 to about 8, about 1 to about 20, about 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 8, about 1.5 to about 20, about 1.5 to about 15, about 1.5 to about 12, about 1.5 to about 10, about 1.5 to about 8, about 2 to about 20, about 2 to about 15, about 2 to about 12, about 2 to about 10, about 2 to about 8, about 2.5 to about 20, about 2.5 to about 15, about 2.5 to about 12, about 2.5 to about 10, about 2.5 to about 8, about 3 to about 20, about 3 to about 15, about 3 to about 12, about 3 to about 10, or from about 3 to about 8% by weight 6'-sialyllactose).
[0168] In various embodiments the extract or composition comprises at least about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.075, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2% by weight disialyllactose as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.001 to about 2, about 0.001 to about 1, about 0.005 to about 1.5, about 0.005 to about 1, about 0.01 to about 2, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 1, about 0.01 to about 0.75, about 0.02 to about 2, about 0.02 to about 1.5, about 0.02 to about 1.25, about 0.02 to about 1, about 0.02 to about 0.75, about 0.03 to about 2, about 0.03 to about 1.5, about 0.03 to about 1.25, about 0.03 to about 1, about 0.03 to about 0.75, about 0.05 to about 2, about 0.05 to about 1.5, about 0.05 to about 1.25, about 0.05 to about 1, or at least about 0.05 to about 0.75% by weight disialyllactose).
[0169] In various embodiments the extract or composition comprises at least about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.075, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, or at least about 2% by weight sialyllactosamine as a percentage of the total solids, and suitable ranges may be selected from between any of these values, (for example, from about 0.001 to about 2, about 0.001 to about 1, about 0.005 to about 1.5, about 0.005 to about 1, about 0.01 to about 2, about 0.01 to about 1.5, about 0.01 to about 1.25, about 0.01 to about 1, about 0.01 to about 0.75, about 0.02 to about 2, about 0.02 to about 1.5, about 0.02 to about 1.25, about 0.02 to about 1, about 0.02 to about 0.75, about 0.03 to about 2, about 0.03 to about 1.5, about 0.03 to about 1.25, about 0.03 to about 1, about 0.03 to about 0.75, about 0.05 to about 2, about 0.05 to about 1.5, about 0.05 to about 1.25, about 0.05 to about 1, or at least about 0.05 to about 0.75% by weight sialyllactosamine).
[0170] In various embodiments the extract or composition comprises, on a dry solids basis, a greater amount of 3'-sialyllactose relative to the amount of 6'- sialyllactose.
[0171] In various embodiments the extract or composition comprises 3'- sialyllactose and 6'-sialyllactose in a ratio of about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1 or 1:2 and suitable ranges may be selected from between any of these values, (for example, from about 10:1 to about 1:1, about 8:1 to about 1:1, about 7: 1 to about 1:1, about 6:1 to about 1:1, about 5: 1 to about 1:1, about 15:1 to about 2:1, about 12:1 to about 2:1, about 10:1 to about 2:1, about 8:1 to about 2:1, about 7:1 to about 2:1, about 6:1 to about 2:1, about 5:1 to about 2:1, about 15:1 to about 3:1, about 12:1 to about 3:1, about 10:1 to about 3:1, about 8:1 to about 3:1, about 7: 1 to about 3:1, about 6: 1 to about 3:1, or about 5: 1 to about 3:1.
[0172] In various embodiments the composition or extract further comprises other sialic acid-containing compounds including milk fat globular membrane (MFGM), sialic acid-containing protein and gangliosides.
[0173] The term "sialic acid containing compounds" as used herein includes compounds such as lipids, and protein that contain bound sialic acid. Examples of sialic acid containing compounds present in the compositions or extracts described herein include proteins and gangliosides. Milk fat globular membrane is an example of a source of sialic acid containing compounds present in the compositions and extracts described herein. [0174] In various embodiments the composition or extract comprises at least about 0.5% of other sialic acid containing compounds as a percentage of the total solids.
[0175] The compositions and extracts further comprise neutral
oligosaccharides. In some embodiments the composition or extract comprises added neutral oligosaccharides.
[0176] Neutral oligosaccharides are oligosaccharides that have no charge. Neutral oligosaccharides present in the compositions of the invention include galactooligosaccharides, fructooligosaccharides, N-acetyllactosamine, N- acetylgalactosaminylglucose, N-acetylgalactosaminyllactose, isoglobotriose, 3'- galactosyllactose, 4'-galactosyllactose, 6'-galactosyllactose, novo-lacto-N- pentaose-I, Lacto-N-neotetraose, and Lacto-N-neohexaose. Fructooligosaccharides can be detected by methods such as described in Cuany, Denis, Thierry Benet, and Sean Austin. 2010 Journal of AOAC International 93 (10) p202-212.
[0177] In some embodiments the composition contains added neutral oligosaccharides.
[0178] In various embodiments the extract or composition comprises at least about 0.01, 0.05, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25 or 30% by weight neutral oligosaccharides, and suitable ranges may be selected from between any of these values, (for example, from about 0.01 to about 30, about 0.01 to about 20, about 0.01 to about 15, about 0.01 to about 10, about 0.01 to about 6, 0.01 to about 2, about 0.01 to about 0.5, about 0.05 to about 30, about 0.05 to about 25, about 0.05 to about 20, about 0.05 to about 15, about 0.05 to about 10, about 0.1 to about 30, about 0.1 to about 25, about 0.1 to about 20, about 0.1 to about 15, about 0.1 to about 10, about 0.2 to about 30, about 0.2 to about 25, about 0.2 to about 20, about 0.2 to about 15, about 0.2 to about 10, about 0.25 to about 30, about 0.25 to about 25, about 0.25 to about 20, about 0.25 to about 15, about 0.25 to about 10, about 0.5 to about 30, about 0.5 to about 25, about 0.5 to about 20, about 0.5 to about 15, about 0.5 to about 10, about 1 to about 30, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, about 2 to about 30, about 2 to about 25, about 2 to about 20, about 2 to about 15, about 2 to about 10, about 5 to about 30, about 5 to about 25, about 5 to about 20, about 5 to about 15, about 10 to about 30, about 10 to about 25, or about 10 to about 20% by weight neutral oligosaccharides). [0179] In various embodiments the extract or composition comprises less than about 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% by weight protein and non-protein nitrogen, and suitable ranges may be selected from between any of these values, (for example, from about 1 to about 20, about 1 to about 15, about 1 to about 10, about 1 to about 8, about 1 to about 6, about 1 to about 5, about 2 to about 20, about 2 to about 16, about 2 to about 11, about 2 to about 9, about 2 to about 8, about 2 to about 7, about 3 to about 20, about 3 to about 15, about 3 to about 13, about 3 to about 9, about 3 to about 8, about 3 to about 6, about 4 to about 20, about 4 to about 15, about 4 to about 10, about 4 to about 9, about 4 to about 8, about 4 to about 7, about 5 to about 2,0 5 to about 16, about 5 to about 10, about 5 to about 8, about 5 to about 7, about 6 to about 20, about 6 to about 17, about 6 to about 11, about 6 to about 10, about 6 to about 9, about 7 to about 20, about 7 to about 15, about 7 to about 10, about 8 to about 20, about 8 to about 17, about 8 to about 12, about 9 to about 20, about 9 to about 15, about 10 to about 20, about 10 to about 16, about 11 to about 20 11 to about 16, about 12 to about 20, about 12 to about 17, about 13 to about 20, about 13 to about 16, about 14 to about 20, about 14 to about 18 or about 15 to about 20% by weight protein and non-protein nitrogen).
[0180] As used herein the term "non-sialyloligosaccharide sugars" refers to all sugars in the composition except for sialyloligosaccharides. Non- sialyloligosaccharide sugars include disaccharides (particularly lactose),
monosaccharides (including glucose and galactose) and other oligosaccharides (including neutral oligosaccharides and acidic oligosaccharides).
[0181] In various embodiments the extract or composition comprises less than about 85, 84, 83, 82, 81, 80, 79, 78, 77, 75, 70, 65, 60, 55, 50, 45, 40, 35, or 30% by weight non-sialyloligosaccharide sugars, and suitable ranges may be selected from between any of these values, (for example, from about 30 to about 85, about 30 to about 80, about 30 to about 75, about 40 to about 85, about 40 to about 80, about 40 to about 75, about 50 to about 85, about 50 to about 80, about 50 to about 75, about 50 to about 70, about 55 to about 85, about 55 to about 80, about 55 to about 75, about 55 to about 70, about 60 to about 85, about 60 to about 80, about 60 to about 75, about 60 to about 70, about 65 to about 85, about 65 to about 80, about 65 to about 75, about 65 to about 70, about 70 to about 85, about 70 to about 80, or from about 70 to about 75% by weight non- sialyloligosaccharide sugars). [0182] In various embodiments the extract or composition comprises less than about 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or less than about 1% by weight ash, and suitable ranges may be selected from between any of these values, (for example, from about 0 to about 15, about 0 to about 12, about 0 to about 10, about 0 to about 7, about 0 to about 5, 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 7, about 1 to about 5, about 2 to about 15, about 2 to about 12, about 2 to about 10, about 2 to about 7, about 3 to about 15, about 3 to about 12, about 3 to about 10, about 3 to about 7, about 4 to about 15, about 4 to about 12, about 4 to about 10, about 4 to about 7, about 5 to about 15, about 5 to about 12, or about 5 to about 10% by weight ash).
8. Nutritional formulations
[0183] The extracts and compositions of the invention are suitable for use in nutritional formulations including maternal formulas, infant formulas, follow-on formulas, growing-up formulas, paediatric formulas, human milk fortifiers, children's foods or drinks, maternal supplements, maternal nutritional formulations, fermented foods, UHT milks, UHT drinking yoghurts, acidified milk drinks, UHT powders, medical foods, sports nutritional formulations, or formulations for senior or aged populations.
[0184] The term "maternal formula" as used in this specification means a composition for pregnant woman to take during pregnancy. The term "infant formula" as used in this specification means a composition for infants aged between 0 days and 6 months old. The term "follow-on formula" as used in this specification means a composition for infants aged 6 months to 1 year. The term "growing up formula" as used in this specification means a composition for infants and children aged 1 year upwards. Growing-up formula includes growing-up milk powders or GUMPs. The term "paediatric formula" as used in this specification means a composition for children aged from birth.
[0185] It will be appreciated by those skilled in the art that the age ranges for the different compositions: "infant formula", "follow-on formula, "growing-up formula" and "paediatric formula" can vary from child to child depending on the individual's development. These products may be in liquid form as concentrates or ready-to-drink liquids or provided as powder concentrates. [0186] In various embodiments the nutritional formulation comprises at least about 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4 or 5% of the sialyloligosaccharide- containing extract or composition, and suitable ranges may be selected from between any of these values, (for example, from about 0005 to about 5, about 0.005 to about 3, about 0.005 to about 1, about 0.005 to about 0.5, about 0.005 to about 0.05, about 0.01 to about 5, about 0.01 to about 3, about 0.01 to about 1, about 0.01 to about 0.5, about 0.01 to about 0.1, about 0.05 to about 5, about 0.05 to about 4, about 0.05 to about 1, about 0.05 to about 0.1, about 0.1 to about 5, about 0.1 to about 4, about 0.1 to about 1, about 0.1 to about 0.5, about 0.5 to about 5, about 0.5 to about 3, about 0.5 to about 1, about 1 to about 5, about 1 to about 4, about 1 to about 3, about 2 to about 5, about 2 to about 4, about 3 to about 5% of the sialyloligosaccharide to about containing extract or composition).
[0187] In various embodiments the nutritional formulation comprises at least about 0.005% total sialyloligosaccharides on a weight/volume basis.
8.1 Formulas for infants and children
[0188] In various embodiments the infant formula comprises at least about 0.17% total sialyloligosaccharides on a weight/weight solids basis.
[0189] In various embodiments the follow-on formula comprises at least about 0.19% total sialyloligosaccharides on a weight/weight solids basis.
[0190] In various embodiments the growing-up formula comprises at least about 0.19% total sialyloligosaccharides on a weight/weight solids basis.
[0191] In various embodiments the maternal formula comprises at least about 0.15% total sialyloligosaccharides on a weight/weight solids basis.
[0192] As used herein, infant formulas refer to nutritional formulas for infants aged 0-6 months, follow-on formula for infants aged 6 months to 1 year, growing up formula for infants aged 12 months onwards. Maternal formulas are for woman trying to conceive, pregnant, or breastfeeding.
[0193] Nutritional formulations comprising the sialyloligosaccharide extracts and compositions described herein may be incorporated into formulations known in the art. Suitable formulations and ingredients will be apparent to those skilled in the art. [0194] In one embodiment, the extract or composition delivers more humanised milk-based nutrition in relation to, for example, 3'-sialyllactose. "More humanised" means that the extract or composition is compositionally or functionally more similar to human breast milk than the unmodified or unprocessed form of the source material in relation to, for example, 3'-sialyllactose.
[0195] One example of the increased humanisation of the extract or composition is in relation to >3-4 months post-partum infants through the ratio of 3'-sialyllactose and 6'-sialyllactose.
[0196] The applicant has determined that the complement and concentration of sialyloligosaccharides for infants and children varies at different ages and stages of development. In particular, the ratio of 3'-sialyllactose and 6'-sialyllactose varies as the infant or child develops.
[0197] In one embodiment, the optimal ratio of 3'-sialyllactose and 6'- sialyllactose may be administered in compositions specifically tailored for infants or children in particular age groups or developmental stages.
[0198] In one embodiment the composition provides a greater amount of 3'- sialyllactose than 6'-sialyllactose infants aged 4-6 months and above.
[0199] In other embodiments the composition provides nutrition to an infant of less than 3 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5: 1. In one embodiment the composition is an infant formula.
[0200] In various embodiments the composition is a composition for providing nutrition to an infant of less than 6 months of age comprising 3'- sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5 : 1. In one embodiment the composition is an infant formula.
[0201] In various embodiments the composition is a composition for providing nutrition to an infant of from about 6 months to about 12 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5 : 1. In one embodiment the composition is an follow-on formula.
[0202] In various embodiments the composition is a composition for providing nutrition to an infant of 12 months of age or over comprising 3'- sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1 : 2. In various embodiments the composition is a growing up formula or a paediatric formula.
[0203] A paediatric formula is given by way for example below.
Nutrients Average quantity per 100
mL of prepared formula
Energy 280 kJ
Protein 1.7 g
Fat 3.4 g
- Linoleic Acid 496 mg
- alpha Linolenic Acid 58.6 mg
- Docosahexaenoic Acid (DHA) 7.2 mg
- Arachidonic Acid (ARA) 9.0 mg
Carbohydrate
Lactose 7.4 g
3'-and 6'-Sialyllactose 40.7 mg
Sialyllactosamine 3.3 mg
Vitamins
Vitamin A 64.1 μg RE
Vitamin B6 51.5 μg
Vitamin B12 0.5 μg
Vitamin C 11.7 mg
Vitamin D3 0.9 μg
Vitamin E 1.5 mg TE
Vitamin Kl 6.4 μg
Biotin 4.3 μg
Niacin (B3) 636 μg
Folate 13.4 μg
Pantothenic Acid (B5) 624 μg
Riboflavin (B2) 155 μg
Thiamin (Bl) 67.4 μg
Minerals
Calcium 64.7 mg
Copper 54.8 μg
Iodine 11.9 μg
Iron 0.8 mg
Magnesium 8.3 mg
Manganese 11.6 μg
Phosphorus 43.1 mg
Selenium 2.3 μ9
Zinc 0.6 mg Chloride 65.1 mg
Potassium 77.4 mg
Sodium 23.4 mg
Other Nutrients
Choline 12.1 mg
Inositol 10.4 mg
Taurine 5.9 mg
Prebiotics (FOS) 73.4 mg
Nucleotides
Adenosine 5' monophosphate 0.9 mg
Cytidine 5' monophosphate 1.4 mg
Inosine 5' monophosphate 0.5 mg
Uridine 5' monophosphate 0.7 mg
Guanosine 5' monophosphate 0.2 mg
9. Maintaining or increasing brain function or development
[0204] Nutritional formulations, sialyloligosaccharide-containing extracts or compositions described herein may be administered to maintain or increase brain function or development in a normal subject.
[0205] Subjects who may benefit from administration of the formulations or compositions include neonates, infants, toddlers, children, pregnant women, breastfeeding mothers, adults, athletes, other sportspersons or the elderly.
[0206] As used herein, the term "normal subject" refers to a subject who is not suffering from a disease or condition associated with impaired brain function or development.
[0207] An "effective amount" is the amount required to confer therapeutic, prophylactic effect. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich, et al. (1966). Body surface area can be approximately determined from height and weight of the subject. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537. Effective doses also vary, as recognized by those skilled in the art, dependent on route of administration, carrier usage, and the like.
[0208] As used herein, the terms "to maintain brain function or
development" or "maintaining brain function or development" are used
interchangeably and generally refer to preventing the decline of or maintaining brain function, maintaining normal brain development or preventing delay in brain development. These terms include preventing delayed brain development, maintaining the viability or function of neuronal cells, maintaining cognitive development, preventing delayed cognitive development, maintaining cognitive performance, preventing cognitive decline, maintaining or preventing decline of learning ability, memory or attention span, maintaining the ability of a subject to cope with stress, maintaining the level of gangliosides in the brain, maintaining the level of protein-bound sialic acid in the brain e.g. Neural Cell Adhesion Molecule (NCAM), maintaining blood, nutrient or oxygen flow to the brain, maintaining synaptogenesis, maintaining the activity of the gut/brain axis, or maintaining neurogenesis.
[0209] As used herein, the terms "to increase brain health or development" or "increasing brain health and development" are used interchangeably herein and generally refer to enhancing or improving brain function and advancing brain development. These terms include increasing cognitive development or
performance, increasing learning, memory or attention span, increasing the ability of a subject to cope with stress, increasing the level of gangliosides in the brain, increasing the level of protein-bound sialic acid in the brain e.g. Neural Cell Adhesion Molecule (NCAM), increasing blood, nutrient or oxygen flow to the brain, increasing synaptogenesis, increasing the activity of the gut/brain axis or increasing neurogenesis.
[0210] Optimal cognitive development is a key part of infant and child development. Therefore any agent shown to increase cognitive development will have wide benefits for infants and children.
[0211] A wide variety of methods to assess cognitive development are well known to those skilled in the art. It will be apparent that particular methods may be preferred depending on the nature of the cognition to be assessed, the
characteristics or identity (such as but not limited to the species, age, health or wellbeing) of the subject, or other factors as may be applicable. For example, methodology useful for the assessment of cognitive development in non-human subjects includes the Morris Water Maze Test and the Novel Object Recognition Task Test, as described in Example 1. Examples of methodology useful for the assessment of cognitive development in human subjects includes the tools summarised in Table 1. Table 1 - Examples of methods for assessment of human development
Parameter Tool used Age Components of Reference
group tool
Cognitive and Bayley Scales 0-3 Global The Essentials of
Motor of Infant years assessments of Bayley Scales of
Development. Development, cognitive and Infant Development II
Version 2, motor Assessment, Maureen development M. Black, Kathleen assesses the Matula. New York: motor (fine and John Wily, 1999. gross), language ISBN : 978-0-471-
(receptive and 32651-9
expressive), and
cognitive
development
Intelligence Weschler 2.6- Verbal WPPSI (Wechsler Quotient Preschool & 7.3 comprehension Preschool and Primary primary scale years Scale of Intelligence - Third Edition, 2002) published : Harcourt Assessment, David Wechsler
Memory Children's 5 - 8 1. Attention and Children's Memory
Memory Scale years working memory Scale (CMS) 1997,
2. Verbal and Morris Cohen
Visual memory
3. Short Delay
and long delay
4. Recall and
recognition
5. Learning
Characteristics
Development Denver 0-6 General childhood www.denverii.
Developmental years development com
Materials
Executive Wisconsin card 5+ 1. Preservative Wisconsin Card functioning sorting test years thinking Sorting Test:
2. Assess abstract Computer Version 4 reasoning (WCST: CV4),
Robert K. Heaton.
Academic School Report School Report Cards
Achievement Cards Performance (Academic
Performance in School Setting), Young Children Achievement Test, Wayne P. Hresko
[0212] In one embodiment the administration of the composition of the invention to an individual leads to an increase in glycerophosphorylcholine (GPC) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values. [0213] In one embodiment the administration of the composition of the invention to an individual leads to an increase in glutamine (Glu) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0214] In one embodiment the administration of the composition of the invention to an individual leads to an increase in myo inositol (Ins) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0215] In one embodiment the administration of the composition of the invention to an individual leads to a decrease in Lip09 in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0216] In one embodiment the administration of the composition of the invention to an individual leads to a decrease in macromolecules (MM) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0217] In one embodiment the administration of the composition of the invention to an individual leads to an increase in N-Acetylaspartylglutamic acid (NAAG) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
[0218] In one embodiment the administration of the composition of the invention to an individual leads to an increase in the glutamate-glutamine complex (Glx) in the brain in that individual of at least about 10, 15, 20, 25, 30, 35, 40 or 50%, and suitable ranges may be selected from between any of these values.
10. Cognitive disease
[0219] In one embodiment the extract or composition of the present invention can be used to treat or improve diseases that include cognitive decline as a symptom. For example, the use of the extract or composition can reduce the rate of cognitive decline, maintain cognition in the patient, or improve cognitive ability in that patient. Examples of diseases that include cognitive decline as a symptom of that disease include Alzheimer's disease, Parkinson's disease, Huntington's disease or dementia. [0220] Therefore, in one embodiment the invention relates to the use of a extract or composition as described in the treatment or prevention of cognitive decline associated with any one or more or age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia, infantile onset severe development delay (associated with mutations with the gene encoding for N-acetylneuraminic acid) or distal myopathy with rimmed vacuoles (DMRV) comprising administering an effective amount of a sialyloligosaccharide-containing extract produced.
EXAMPLE 1
[0221] Sialyloligosaccharide-containing extracts are produced using four different methods. The sialyloligosaccharide, protein, non-protein nitrogen, lactose and ash content is determined.
1. Method A
[0222] A sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
[0223] The source material is heated at greater than 67°C for at least two minutes to precipitate minerals in the mother liquor. Insoluble minerals and some protein are removed by centrifugation.
[0224] The demineralised source material is subjected to an enzyme reaction step with β-galactosidase to degrade lactose to galactose and glucose.
[0225] Ultrafiltration is performed at 50°C to 70°C, 2-10 bar using a membrane with a pore size of 3-20 kDa to remove protein. [0226] The ultrafiltration permeate comprising saccharides, soluble minerals and sialyloligosaccharides is subjected to nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove galactose, glucose and soluble minerals.
[0227] The nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate. Optionally, reverse osmosis and/or nanofiltration are performed prior to evaporation.
[0228] Optionally, a second enzyme reaction is conducted using β- galactosidase to produce glucose and galactose or to produce GOS.
[0229] The concentrated retentate or enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
[0230] The liquid extract is optionally dried to produce a dried extract.
Optionally, the liquid extract is crystallised before drying.
2. Method B
[0231] A sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
[0232] The source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor. Insoluble minerals and some protein are removed by centrifugation.
[0233] The demineralised source material is subjected to ultrafiltration performed at 50-70°C, 2-10 bar using a membrane with a pore size of 3-20 kDa to remove protein.
[0234] The ultrafiltration permeate comprising sugars, soluble minerals and sialyloligosaccharides is subjected to nanofiltration/diafiltration performed at 25°C- 55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove small sugars and soluble minerals.
[0235] The nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate. Optionally, reverse osmosis and/or nanofiltration are performed prior to evaporation. [0236] An enzyme reaction is conducted using β-galactosidase to produce glucose and galactose or to produce GOS.
[0237] The enzyme product is subjected to decolourisation and filtration to produce a sialyloligosaccharide-enriched liquid extract.
[0238] The liquid extract is optionally dried to produce a dried extract.
Optionally, the liquid extract is crystallised before drying.
3. Method C
[0239] A sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
[0240] The source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor.
[0241] The source material is subjected to ceramic filtration performed at 50°C to 90°C, 1-6 bar using a membrane with a pore size/MWCO of 300 Da to 2 m to remove insoluble minerals and protein.
[0242] The demineralised, deproteinised material is subjected to an enzyme reaction step with β-galactosidase to degrade lactose to galactose and glucose.
[0243] The material is subjected to nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove galactose, glucose and soluble minerals.
[0244] The nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate. Optionally, reverse osmosis and/or nanofiltration are performed prior to evaporation.
[0245] Optionally, a second enzyme reaction is conducted using β- galactosidase to produce glucose and galactose or to produce GOS.
[0246] The concentrated retentate or enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
[0247] The liquid extract is optionally dried to produce a dried extract.
Optionally, the liquid extract is crystallised before drying. 4. Method D
[0248] A sialyloligosaccharide-containing material comprising the mother liquor from lactose crystallisation is provided.
[0249] The source material is heated at greater than 67 °C for at least two minutes to precipitate minerals in the mother liquor.
[0250] The source material is subjected to ceramic filtration performed at 50-90°C, 1-6 bar using a membrane with a pore size/MWCO of 300 Da to 2 μηη to remove insoluble minerals and protein.
[0251] The demineralised, deproteinised material is subjected to
nanofiltration/diafiltration performed at 25-55°C, 30-50 bar using a membrane with a pore size of 100-250 Da to remove sugars and soluble minerals.
[0252] The nanofiltration retentate enriched in sialyloligosaccharides is subjected to evaporation to produce a concentrated retentate. Optionally, reverse osmosis and/or nanofiltration are performed prior to evaporation.
[0253] A second enzyme reaction is conducted using β-galactosidase to produce glucose and galactose or to produce GOS.
[0254] The enzyme product is subjected to decolourisation and optionally filtration to produce a sialyloligosaccharide-enriched liquid extract.
[0255] The liquid extract is optionally dried to produce a dried extract.
Optionally, the liquid extract is crystallised before drying.
5. Results
[0256] The composition of the sialyloligosaccharide-enriched extracts produced by methods A-D is set out in Table 1. Table 1: Composition of sialyloligosaccharide-containing extracts produced by methods A-D
Component % by weight on a
dry solids basis
Sialyloligosaccharides 5-30%
3'-sialyllactose 5-30%
6'-sialyllactose 2-10%
disialyllactose 0.01-1%
sialyllactosamine 0.01-1%
Protein and non5-25%
protein nitrogen
Sugars excluding 20-80%
sialyloligosaccharides
Ash 0-5%
EXAMPLE 2
[0257] An animal model (piglets) was used to determine the effect of sialyloligosaccharide-enriched compositions on cognition.
1. Animal model
[0258] The brain structure and function of piglets closely resembles that of preterm human infants (Pond, et al., Proc. Soc. Exp. Biol. Med., 2000. 223(1) : p. 102-8; Moughan, et al., World Rev. Nutr. Diet, 1992. 67 : p. 40-113).
[0259] The newborn piglet, similar to humans, is less developed and its body weight is relatively small in relation to its mature weight. For this reason, both newborn piglets and low-birth-weight infants are vulnerable to developmental deficits post-partum. It has been reported that naturally farrowed piglets born small for gestational age (SGA) (0.7-1.0 kg BW) have spatial learning deficits and abnormal development of white matter (Radlowski et a/., PLoS One, 2014. 9(3) : p. e91951). The piglet is a tractable translational model that can be used to
investigate SGA-associated cognitive deficits and potential interventions. Moreover, the piglet's digestive system shares similar physiology and anatomical structure with human infants, and has comparable nutrient requirements.
2. Trial design
[0260] Three-day-old male domestic piglets (n=48) were randomised to one of three groups (n= 16/group) and fed formula comprising different sialyloligosaccharides from 3 to 37 days of age. The trial groups are described in Table 2.
[0261] The piglets were housed two per pen in a temperature-conditioned room on a 12-h light (08 : 00-20 : 00) and dark (20: 00-08 : 00) cycle.
[0262] 180 g of SL enriched milk powder (or plain milk powder for control) was mixed with 850 mL of warm water to form the formulation. The piglets then received 285 mL formula/kg/day for the first two weeks and 230 mL/kg/day for the remaining weeks at 8 : 00h, 13: 00h, 18: 00h and 22: 30h, with an extra 50 mL formula/kg/day supplied at the last feeding.
Table 2: Trial Groups
Group Composition of administered formula
Total 3'sialylactose 6'-sialyllactose 6'sialyllactos sialyloligosaccharides amine
Group 1 Control Group - - -
Group 2 9.5 g/kg of powder 7.6 g/kg of 1.9 g/kg of - powder powder
Group 3 9.5 g/kg of powder 7.0 g/kg of 1.7 g/kg of 0.72 g/kg of powder powder powder
[0263] Body weight, milk intake and health status of the piglets was assessed daily. Blood samples were collected at time of euthanasia for
determination of Cortisol and sialyloligosaccharide levels in red blood cell (RBC) membranes.
3. Brain sample collection
[0264] At day 38-39 of age, piglets were euthanased by injection with lethabarb without recovering from the anaesthesia of 2-3.5% isoflurane for MRS scan. Tissue samples from different region of the brain were collected and stored at -80°C. Analysis was conducted on these samples using methods described
previously (see Chen, et a\. Molecular Neurobiology 2015. 52(1) : p. 256-269; Chen et al., Br. J. Nutr., 2014. 111(2) : p. 332-41 ; Wang et al., Am. J. Clin. Nutr., 2007. 85(2) : p. 561-9; 4. Discrimination testing
4.1 Methods
[0265] Two tests were undertaken : an 'easy' task (Task 1) and a more 'difficult' task (Task 2) using an 8-arm radial maze.
[0266] For both tasks, accessible milk was provided in one arm and inaccessible milk in the remaining 7 arms so that all arms have the same smells, in order to prevent olfactory learning.
[0267] For both tasks, a visual cue consisting of three black dots placed on the door with accessible milk in the arm.
[0268] For Task 1, a single black dot visual cue was placed on the remaining seven doors with inaccessible milk. For Task 2, a visual cue with two black dots was placed on the remaining seven doors.
[0269] 40 trials for each task were conducted over a 10-day period beginning on day 23. Each piglet was introduced into the 8-arm radial maze individually.
[0270] Assessment of learning capacity was determined based on the number of trials taken to successfully learn the visual cue. Learning was quantified using the number of mistakes and successes in finding the accessible milk arm during each trial. A mistake was registered each time the piglet enters or puts its whole head through the wrong door. A success was registered when the piglet enters the correct door. The criterion to learn the visual cue is a maximum of one mistake in three consecutive trials. An overhead video camera records continuously during the learning and memory test and a trained observer records the results manually. All the tests are conducted by trained staff blinded to trial group. Results were corroborated by independent analysis of the video material.
[0271] To reduce stress and familiarise the piglets with the test protocol, two piglets from the same pen were allowed to enter the maze at the start of the learning period.
4.2 Results
[0272] There was no significant difference in the 5 min short-term memory test between the groups. The Group 3 piglets performed better in the 3 hr long- term memory trial as shown in Figure 3. [0273] As shown in Figure 4, the Group 3 piglets performed better in the difficulty taks based on the criteria of no more than one mistake over four consectutive trials with P< 0.05 using Cox regression analysis.
5. Structural and metabolic assessment of the brain using magnetic resonance spectroscopy (MRS)
5.1 Methods
[0274] Proton magnetic resona nce spectroscopy ^H-M RS) was performed to assess local cerebral metabolism. In vivo MRI is a powerful tool that enables morphometric imaging of the postnatal piglet brain.
[0275] Briefly, the animals were placed in right lateral position in a 3T MR sca nner (Siemens Skyra, Erlangen) using a 15-channel RF coil for both RF tra nsmission and receive. Anaesthesia was maintained with 2-3.5% isoflurane during the entire MRI scanning procedure using an Anaesthesia Machine (MPI, U .S.A.) . The voxel size was 15x14x20 mm3 on frontal lobe grey matter and white matter (Left to Right 15 mm, Superior to Inferior 14 mm, Anterior to Posterior 20 mm) (Figure 1) . MRS was performed using a localised single-voxel spin echo Point RESolved spectroscopy (PRESS) sequence. This PRESS sequence has three slice- selective RF pulses with the form of 90°- Yi- 180°-( Y2 +Y3)- 180°- Y4-SE, YI = Ύ2 and Y3= Y4. The TE of the SE in this PRESS sequence is equal to YI +Y2+Y3+Y4. In this study, the TR was 2000 ms, there were three TE used : 35 ms (Figure I B), 135 ms (Figure 1C) and 270 ms (Figure I D) .
[0276] Cerebra l development was assessed using 3D volumetric MRI to quantify the absolute volume of cerebral white matter, cortical gray matter and basal structures such as the striatum.
[0277] Diffusion weighted-imaging (DWI) and diffusion-tensor imaging (DTI) was performed to assess the microstructural orga nisation a nd development of the brain.
[0278] Changes in cerebral development was assessed using in vivo MR techniques using a 3.0 Tesla sca nner (Siemens) . Analytical methods included 3D volumetric MRI (macrostructure assessment), d iffusion weighted-imaging and d iffusion-tensor imaging (microstructure assessment), in conjunction with h^-M R Spectroscopy (local cerebral meta bolism) using a whole bra in template, tissue- specific probability maps and anatomical labelling maps reported in Gan, et al. Magn Reson Imaging 32.10 (2014) : 1396-1402.
5.2 Results
[0279] Group 3 showed a significant increase in the absolute levels of glutamate (Glu), myo-inositol (Ins) and glutamate+glutamine (Glx). In addition, there was a significant positive correlation between frontal lobe Ins, N- acetylaspartate (NAA), total NAA, total choline (TCho), total glutathione (Glth), phosphorylcholine (PCh) and total white matter volume or whole brain volume (P<0.01).
[0280] Glutamate is the brain's major excitatory neurotransmitter, and plays an important role in frontal-hippocampal mechanism of learning and memory.
Studies suggest that fast learners are characterised by an early peak in modulated glutamate compared to slow learners (Stanlet J et a/., Functional dynamics of hippocampal glutamate during associative learning assessed with in vivo 1H functional magnetic resonance spectroscopy. 2017 Neuroimage 153: 1 : 189-197).
[0281] Myo-inositol has been implicated in a role in brain development including learning and memory. Abnormally low myo-inositol and glutamate levels in the hippocampus and amygdala have been detected in patients with depression. Glutamate levels in the medial prefrontal cortex and amygdala have significant correlations with executive function and those in the hippocampus with memory function (Shirayama Y et a/., Myo-inositol, Glutamate, and Glutamine in the
Prefrontal cortex, Hippocampus and amygdala in major depression 2017 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2; 2 : 196-204). Significantly reduced concentrations of hippocampal absolute myo-inositol have been detected in patients at high risk for psychosis (Bakker et a/., Hippocampal myo-inositol and glutamate concentrations are predictive of positive symptom severity in ultra-high risk for psychosis. 2013 European Neuropschoparmacology 23; 2 : page S448).
[0282] Also demonstrated were trends for increased GPC (alpha
glycerylphosphorylcholine). GPC has been implicated in neuroprotection (Plangar et al, Journal of Neuro-Oncology (2014) 119 : 2: 253-261), and has provided benefits in patients with cognitive dysfunction (Scapicchio P. (2013) International Journal of Neuroscience 123; 7) and has shown promise as a nutraceutical agent for enhancing cognitive performance and slowing cognitive decline (DeFina P et al., (2013) Journal of Aging Research).
Table 2. Mean (SE) absolute concentrations of metabolites in the different groups. A. TE 35, B. TE 135 and TE 270.
TE35
Metabolites Control Group 2 Group 3 P- Value
GABA 1.455±0.322 1.366±0.272 1.11±0.282
GPC 0.627±0.151 0.847±0.185 0.921±0.2
Glth 1.011±0.189 0.797±0.175 0.8±0.174
Glu 3.004±0.499 3.129±0.417 2.249±0.431
Ins 4.508±0.522 6.118±0.352 5.344±0.234 0.017
Lip09 2.088±0.355 1.931±0.257 1.49±0.257
Lipl3a 4.512± 1.087 3.682±0.575 2.97±0.463
Lipl3b 0.648±0.445 0.095±0.065 0.279±0.151
Lip20 1.787±0.437 1.236±0.407 0.61±0.307 0.112
MM09 3.423±0.593 2.673±0.273 2.59±0.313
MM 12 1.669±0.264 1.366±0.298 1.444±0.156
MM 14 3.972± 1.341 3.433±0.818 3.415±0.673
MM 17 0.567±0.203 0.626±0.171 0.445±0.164
MM20 6.106±0.859 7.827± 1.053 6.045±0.856
NAA 4.447±0.539 4.513±0.512 4.226±0.519
NAAG 2.014±0.783 1.581±0.481 2.188±0.616
PCh 1.169±0.244 1.026±0.228 0.973±0.26
Scyllo 0.706±0.289 0.35±0.058 0.304±0.057
TNAA 6.461±0.328 6.095±0.24 6.414±0.249
TCho 1.796±0.129 1.873±0.097 1.894±0.103
Glx 3.385±0.562 3.656±0.427 2.318±0.453 0.116
TLM09 5.511±0.67 4.605±0.393 4.08±0.407
TLM 13 10.801±2.589 8.576±0.908 8.109±0.971
TLM20 7.893± 1.16 9.063± 1.133 6.655± 1.073
TE135ms
Metabolites Control Group 2 Group 3 P-Value
GABA 1.071±0.217 1.152±0.362 1.131±0.205 GPC 2.28±0.37 1.999±0.411 1.855±0.355
GIth 1.418±0.209 1.183±0.118 1.111±0.117
Glu 7.081±0.519 7.703±0.359 7.462±0.486
Ins 13.705± 1.024 13.432±0.738 12.466±0.606
Lip09 0.514±0.13 0.221±0.087 0.054±0.036 0.004
Lipl3a 2.288±0.883 0.552±0.236 0.51±0.357 0.05
Lipl3b 0.367±0.144 0.187±0.099 0.492±0.147
Lip20 0.005±0.005 0±0 0.01±0.01
MM09 0.125±0.093 0.276±0.176 0.015±0.015
MM 12 0.013±0.012 0.116±0.078 0.126±0.057
MM 14 2.755± 1.856 1.476±0.559 0.473±0.218
MM 17 0.299±0.12 0.215±0.106 0.211±0.075
MM20 3.997±0.888 6.136±0.861 3.491±0.809 0.521
NAA 9.89±0.619 10.914±0.702 10.015±0.735
NAAG 4.852±0.634 4.129±0.558 4.996±0.719
PCh 2.296±0.394 2.754±0.419 2.926±0.413
PCr 4.278±0.402 3.976±0.464 4.136±0.388
Scyllo 1.277±0.116 1.414±0.111 1.265±0.123
Tau 2.056±0.378 2.071±0.403 1.515±0.363
TNAA 14.742±0.62 15.043±0.492 15.011±0.582
TCho 4.576±0.222 4.752±0.174 4.781±0.14
TCr 10.228±0.45 10.497±0.335 10.338±0.241
Glx 8.783±0.278 9.072±0.334 8.968±0.523
TLM09 0.639±0.188 0.496±0.241 0.069±0.041 0.074
TLM 13 5.424±2.583 2.332±0.655 1.601±0.468
TLM20 4.002±0.889 6.136±0.861 3.501±0.806 0.079
TE270ms
Metabolites Control Group 2 Group 3 P-Value
GABA 1.009±0.371 0.787±0.382 0.981±0.369
GPC 2.345±0.701 2.108±0.71 3.902± 1.223
GIth 5.664±0.4 5.938±0.406 5.557±0.589
Glu 11.896±0.82 12.201±0.63 15.245±0.909 0.009
Ins 17.745±0.961 19.017± 1.151 22.113± 1.303 0.031 Lip09 0.443±0.153 0.346±0.147 0.241±0.114
Lipl3a 0.213±0.118 0.366±0.366 0.456±0.317
Lipl3b 0.033±0.033 0.298±0.159 0.44±0.264
MM09 2.036±0.256 2.05±0.265 1.832±0.317
MM 12 0.044± 0.044 0.049±0.047 0±0
MM 14 3.148±0.59 3.143±0.797 2.116±0.732
MM 17 0.837±0.25 1.058±0.38 0.536±0.225
MM20 0.027±0.027 1.69± 1.065 1.823± 1.118
NAA 31.653± 1.594 32.794± 1.996 31.519±2.647
NAAG 8.56±0.888 8.592±0.988 10.979± 1.86
PCh 8.739±0.875 9.097±0.773 7.849± 1.151
Scyllo 2.796±0.157 2.825±0.229 3.05±0.207
TNAA 40.212± 1.424 41.386± 1.493 42.497± 1.554
TCho 11.084±0.51 11.205±0.461 11.751±0.561
Glx 19.934±0.829 20.122±0.566 23.811± 1.126 0.004
TLM09 2.073±0.258 2.396±0.27 2.479±0.312
TLM 13 3.013±0.685 3.856±0.781 3.438±0.558
TLM20 2.55± 1.16 1.69± 1.065 0.814±0.785
[0283] The significant difference (P< 0.05) shown above in Table 2 is based on a general linear model (univariate ANOVA) with Bonferroni's adjustment for multiple comparisons.
[0284] Thus the sialyloligosaccharides can alter many important brain metabolites and neurotransmitters required for optimising neurodevelopment in piglets.
6. Quantitative biochemical analyses
6.1 Method
[0285] The level of polysialic acid (polySia) was measured. PolySia is a unique polymer of sialic acid that modifies neural cell adhesion molecule (NCAM) spatiotemporally in embryonic brains, and is involved in cell migration, neural outgrowth, axonal guidance, synaptic plasticity, and the development of normal neural circuits and neurogenesis. PolySia expression is found in the olfactory bulb, hippocampus, subventricular zone, thalamus, prefrontal cortex, and amygdala, where neural plasticity, remodeling of neural connections, or neural generation is ongoing. PolySia may regulate various neurologically active molecules, such as neurotrophic factor (BDNF), growth factor (FGF2), and neurotransmitter
(dopamine), to regulate their involved signaling.
[0286] Immunofluorescence was used to carry out biochemical analysis. Consecutive coronal sections of 8 m thickness from the piglet's hippocampus and frontal cortex were prepared using a freezing microtome. Brain sections were fixed in ice-cold 4% paraformaldehyde for 15 min, rinsed in phosphate-buffered saline (PBS), and permeabilised with 0.3% Triton X-100 for 30 min, followed by blocking with 0.3% goat serum in PBS (RT). Sections were then incubated overnight (4°C) with a primary antibody specific for detecting the polySia moiety of polySia-NCAM (1 : 200; MAB5324, Millipore, USA). After washing with PBS, sections were incubated with Alexa Fluor 488-conjugated secondary antibody (1 : 200; 115-545-075, Jackson ImmunoResearch, USA) for 1 hr. at room temperature. All sections were
counterstained with DAPI (H-1200, VECTOR laboratories, USA). Images were obtained and analysed using a confocal microscope.
[0287] Western blot was used to analyse polySia-NCAM expression levels and other problem markers according to previous methods (Chen 2014, Zhu 2015). The dilution of the primary antibody (anti-polySia-NCAM antibody, MAB5324, Millipore) was 1 : 1000, and GAPDH was used as a control for the amount of protein loaded on each gel and detected using an anti-GAPDH mAb (MAB5718, R&D System, USA) at 0.05 μg/mL. The secondary antibody (anti-mouse IgG, A4416, Sigma-Aldrich, USA) was used as the dilution of 1 : 10000. Quantification of the protein bands was carried out by scanning the films using the Image Analyses Software (Quantity One, Bio- Rad, USA). The density of bands on all films was determined under non-saturating conditions.
6.2 Results
[0288] There was no significant difference in polySia-NCAM expression in hippocampus between groups using western blot method. However there was significantly higher PolySia expression in the frontal cortex in two treatment group compared with the control (P<0.001, one way ANOVA, Figure 4).

Claims

CLAIMS:
1. A method of producing sialyloligosaccharides from a liquid source that comprises sialyloligosaccharides, carbohydrates and minerals by subjecting the liquid source to a process comprising
a) heating the liquid source to a temperature of from about 67°C, b) subjecting the heat-treated liquid source to
i) a filtration step with a heat-resistant filter at a temperature of about 35 to about 95°C to produce a first retentate and first permeate, or
ii) centrifugal separation to produce a light phase and a heavy phase and filtration of the light phase at a temperature of about 50 to about 70°C to produce a first retentate and first permeate, c) subjecting the first permeate to nanofiltration, or nanofiltration and diafiltration, to produce a second retentate and second permeate, and d) concentrating the second retentate,
to produce a sialyloligosaccharide-containing extract.
2. The method of claim 1 wherein the filtration step of (b)(i) is carried out at about 50 to about 90°C to produce a first retentate and first permeate.
3. The method of claim 1 wherein the filtration step of (b)(i) is carried out at about 50 to about 70°C to produce a first retentate and first permeate.
4. The method of any one of claims 1 to 3 wherein the heat resistant filter is a ceramic filter.
5. The method of any one of claims 1 to 4 wherein the filtration step of (b)(ii) is carried out at about 55 to about 70°C to produce a first retentate and first permeate.
6. The method of any one of claims 1 to 5 wherein the filtration step of (b)(ii) is carried out at about 60 to about 70°C to produce a first retentate and first permeate.
7. The method of any one of claims 1 to 6 wherein the filtration step of (b)(ii) is carried out using a heat resistant filter.
8. The method of any one of claims 1 to 7 wherein the heat resistant filter is a ceramic filter.
9. The method of any one of claims 1 to 8 wherein the liquid source comprises a combination of two or more sialyloligosaccharide-containing streams.
10. The method of any one of claims 1 to 9 wherein the liquid source comprises mother liquor as a by-product of lactose crystallisation, a dairy permeate, whey, whey permeate, or a combination of any two or more thereof.
11. The method of any one of claims 1 to 11 wherein the heat treatment is carried out at a temperature of from about 67 to about 100°C.
12. The method of any one of claims 1 to 12 wherein the heat treatment of the liquid source is carried out for about 2 to about 20 minutes.
13. The method step of any one of claims 1 to 13 wherein the heat treatment of the liquid source precipitates about 2% to about 10% of the minerals present in the liquid source.
14. A method of any one of claims 1 to 14 wherein the first permeate comprises less than about 96% of the minerals in the liquid source, and/or
less than about 20% of the protein in the liquid source.
15. A method of any one of claims 1 to 14 wherein the first retentate comprises at least about 3% of the minerals in the liquid source, and/or
at least about 80% of the protein in the liquid source.
16. The method of any one of claims 1 to 16 wherein the filtration step results in a reduction in the amount of insoluble minerals and protein in the first permeate, when compared to the liquid source.
17. The method of any one of claims 1 to 17 wherein the heat resistant filter is a ceramic filter.
18. The method of claim 18 wherein the heat treated liquid source is subjected to ultrafiltration with a ceramic filter.
19. The method of any one of claims 1 to 19 including at least one glycoside hydrolase or polymerase enzyme reaction.
20. The method of claim 20 wherein
a) the first permeate of the filtration step from the heat-resistant filter, b) the light phase,
c) the concentrated second retentate, or d) a combination of any two or more of (a) to (c),
is subjected to the enzyme reaction.
21. The method of claim 20 or 21 wherein the enzyme reaction
increases the molecular size of at least one disaccharide in the source to produce at least one oligosaccharide, or
decreases the molecular size of at least one disaccharide in the source to produce one or more monosaccharides.
22. The method of any one of claims 20 to 22 wherein the enzyme comprises β- galactosidase.
23. The method of any one of claims 20 to 23 wherein the disaccharide comprises lactose.
24. The method of any one of claims 20 to 24 wherein the monosaccharide comprises galactose or glucose.
25. The method of any one of claims 20 to 25 wherein the oligosaccharide comprises one or more galactooligosaccharides.
26. The method of any one of claims 1 to 26 wherein the filtration of the light phase is ultrafiltration.
27. The method of claim 27 wherein the ultrafiltration is conducted at a temperature of from about 50 °C to about 70 °C, and preferably from about 55 °C to about 65 °C.
28. The method of any one of claims 1 to 28 wherein the nanofiltration is conducted at a temperature of from about 25 °C to about 55 °C, preferably about 50 °C.
29. The method of any one of claims 1 to 29 wherein the second permeate comprises soluble minerals and at least one monosaccharide or disaccharide.
30. The method of any one of claims 1 to 30 wherein the second retentate comprises
less than about 70% of the minerals in the first permeate, or
less than about 50% of the non-sialyloligosaccharide sugars in the first permeate.
31. The method of any one of claims 1 to 31 wherein the second retentate comprises
a) at least about 7% by weight sialyloligosaccharides,
b) at least about 0.2% by weight neutral oligosaccharides,
c) less than about 5% by weight protein and non-protein nitrogen, d) less than about 80% by weight non-sialyloligosaccharide sugars, and e) less than about 5% by weight ash.
32. The method of any one of claims 1 to 32 wherein the second permeate comprises
at least about 30% of the minerals in the first permeate, or
at least about 50% of the non-sialyloligosaccharide sugars in the first permeate.
33. The method of any one of claims 1 to 33 wherein the second retentate is subjected to either nanofiltration or reverse osmosis to produce a third retentate.
34. The method of claim 34 wherein the concentrated second retentate, or the third retentate, is subjected to decolourisation.
35. The method of any one of claims 1 to 35 further comprising the steps of subjecting the sialyloligosaccharide-containing extract to crystallisation to produce a crystallised sialyloligosaccharide-containing extract, and drying the sialyloligosaccharide-containing extract or crystallised sialyloligosaccharide-containing extract to produce a dried sialyloligosaccharide-containing extract.
36. The method of any one of claims 1 to 36 wherein the sialyloligosaccharide- containing extract comprises, on a dry solids basis
at least about 7% by weight sialyloligosaccharides,
at least about 0.2% by weight neutral oligosaccharides, less than about 5% by weight protein and non-protein nitrogen, less than about 80% by weight non-sialyloligosaccharide sugars, and less than about 5% by weight ash.
37. The method of any one of claims 1 to 37 wherein the sialyloligosaccharide- containing extract comprises, on a dry solids basis
at least about 5% by weight 3'-sialyllactose, and
at least about 2% by weight 6'-sialyllactose.
38. A sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 38.
39. A sialyloligosaccharide-enriched composition, comprising on a dry solids basis at least about 5% by weight total sialyloligosaccharides comprising i) at least about 5% 3'-sialyllactose by weight of total sialyloligosaccharides,
ii) at least about 2% 6'-sialyllactose by weight of total sialyloligosaccharides,
iii) at least about 0.01% disialyllactose by weight of total sialyloligosaccharides,
iv) at least about 0.01% sialyllactosamine by weight of total
sialyloligosaccharides, and
at least about 0.5% by weight free sialic acid,
at least about 0.2% by weight neutral oligosaccharides, less than about 25% by weight protein and non-protein nitrogen, less than about 80% by weight sugars not including sialyllactose, and less than about 5% by weight ash.
40. The composition of claim 40 comprising, on a dry solids basis, a greater amount of 3'-sialyllactose relative to the amount of 6'-sialyllactose.
41. The composition of claim 40 or 41 comprising 3'-sialyllactose and 6'- sialyllactose in a ratio of from about 65: 1 to about 1.5: 1, from about 15 : 1 to about 1.5 : 1, or from about 8 : 1 to about 1.5 : 1.
42. A nutritional formulation comprising a sialyloligosaccharide-containing extract produced by a method of any one of claims 1 to 38, or a sialyloligosaccharide- enriched composition of any one of claims 40 to 42.
43. The nutritional formulation of claim 43 wherein the nutritional formulation is an infant formula, a follow-on formula, a growing-up formula, a paediatric formula, a human milk fortifier, a children's food or drink, a maternal supplement, a maternal nutritional formulation, a fermented food, a UHT milk, a UHT drinking yoghurt, an acidified milk drink, a UHT powder, a medical food, a sports nutritional formulation, or a formulation for senior or aged populations.
44. The nutritional formulation of claim 43 or 44 further comprising one or more dairy lipids, one or more gaiactooiigosaccharides, one or more probiotic strains, one or more protein hydrolysates, lactoferrin, a milk fat globular membrane (MFGM) formulation, or a combination of any two or more thereof.
45. The nutritional formulation of claim 45 wherein the dairy lipid comprises buttermilk, high fat whey protein concentrate, beta-serum, butter serum, or a combination of any two or more thereof.
46. The nutritional formulation of claim 45 or 46 wherein the probiotic strain comprises a Bifidobacterium lactis or a Lactobacillus rhamnosus strain, or a combination of both Bifidobacterium lactis and Lactobacillus rhamnosus.
47. The nutritional formulation of claim 47 wherein the Bifidobacterium lactis strain comprises Bifidobacterium lactis HN019 (DR10™).
48. The nutritional formulation of claim 47 wherein the Lactobacillus
rhamnosus strain comprises Lactobacillus rhamnosus HN001 (DR20™).
49. A composition for providing nutrition to an infant of less than 6 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from 10 : 1 to about 1.5 : 1 3'-sialyllactose to 6'-sialyllactose.
50. A composition for providing nutrition to an infant of from about 6 months to about 12 months of age comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5: 1 sialyllactose to 6'-sialyllactose.
51. A composition for providing nutrition to an infant of 12 months of age or over comprising 3'-sialyllactose and 6'-sialyllactose in a ratio of from about 10: 1 to about 1.5 : 1 sialyllactose to 6'-sialyllactose.
52. A sialyloligosaccharide-containing extract or composition produced by the method of any one of claims 1 to 38, or as claimed in any one of claims 40 to 42 or 50 to 52, or a nutritional formulation of any one of claims 43 to 49 for use in maintaining or increasing brain function or brain development.
53. A non therapeutic method of maintaining or increasing brain function or brain development, the method comprising administering an effective amount of a sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 39, a composition of any one of claims 40 to 42 or 50 to 52, or a nutritional formulation of any one of claims 43 to 49 in an otherwise healthy subject.
54. A method of claim 54 wherein the sialyloligosaccharide-containing extract comprises
a) one or more structural glycoconjugates of sialic acid,
b) free sialic acid, or
c) both (a) and (b).
55. The method of claim 54 or 55 wherein the extract, composition or nutritional formulation is administered to
a) treat or prevent delayed brain development,
b) maintain the viability or function of neuronal cells,
c) maintain or increase cognitive development,
d) prevent delayed cognitive development,
e) maintain or increase cognitive performance,
f) prevent cognitive decline,
g) maintain or increase learning, memory or attention span,
h) prevent decline of learning ability, memory or attention span, i) maintain or increase ability to cope with stress,
j) prevent decline in brain function,
k) maintain or increase the level of gangliosides in the brain,
I) maintain or increase the level of neural cell adhesion molecule
(NCAM),
m) maintain or increase blood, nutrient or oxygen flow to the brain, n) maintain or increase synaptogenesis,
o) maintain or increase the activity of the gut/brain axis,
p) maintain or increase neurogenesis in an older brain,
q) maintain or increase white matter volume, or
r) a combination of any two or more of a) to q).
56. The method of any one of claims 54 to 56 wherein the subject is a foetal, infant or child subject.
57. The method of any one of claims 54 to 57 wherein the extract, composition or nutritional formulation is administered to a mother during gestation to maintain or increase brain function or development in a foetal subject.
58. The method of any one of claims 54 to 58 wherein the extract, composition or formulation is administered to a breastfeeding mother to maintain or increase brain function or development in an infant subject.
59. A method of treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia comprising administering an effective amount of a sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 32, an extract or composition of any one of claims 33 to 36 or 44 to 46, or a nutritional formulation of any one of claims 37 to 43 to a subject in need thereof.
60. A sialyloligosaccharide-containing extract produced by a method of any one of claims 1 to 39, a composition of any one of claims 40 to 42 or 50 to 52, or a nutritional formulation of any one of claims 43 to 49 for treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia, infantile onset severe development delay (associated with mutations with the gene encoding for N-acetylneuraminic acid) and distal myopathy with rimmed vacuoles (DMRV).
61. Use of a sialyloligosaccharide-containing extract produced by the method of any one of claims 1 to 32, or a composition of any one of claims 33 to 36 or 44 to 46, in the manufacture of a formulation for treating mild cognitive impairment associated with any one or more of age-related cognitive decline, dementia, Alzheimer's disease, vascular disease, frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cognitive impairment associated with schizophrenia, chemotherapy-induced neuropathy, Down's syndrome, Korsakoff's disease, cerebral palsy, epilepsy, neuronal ischemia, neuronal reperfusion injury, neuronal trauma, neuronal haemorrhage, neuronal infection, stroke, neuronal exposure to a toxic substance, age-related mental disorders, anxiety disorders, age-related depression, dementia associated with microvascular disorders (such as diabetes, hypotension, stroke induced vascular dementia, and obesity), dementia associated with a disorder of the immune system, dementia associated with a central nervous system (CNS) disorder, dementia associated with hypotension, dementia associated with obesity or vascular dementia or infantile onset severe development delay
(associated with mutations with the gene encoding for N-acetylneuraminic acid) and distal myopathy with rimmed vacuoles (DMRV).
PCT/IB2017/054610 2016-07-28 2017-07-28 Dairy product and process WO2018020473A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA3030809A CA3030809A1 (en) 2016-07-28 2017-07-28 Sialyloligosaccharide product and process
AU2017302181A AU2017302181B2 (en) 2016-07-28 2017-07-28 Dairy product and process
RU2019105567A RU2019105567A (en) 2016-07-28 2017-07-28 DAIRY PRODUCT AND METHOD
JP2019504767A JP2019523278A (en) 2016-07-28 2017-07-28 Dairy products and processes
CN201780046024.2A CN109715169A (en) 2016-07-28 2017-07-28 Dairy products and technique
NZ750365A NZ750365A (en) 2016-07-28 2017-07-28 Dairy product and process
SG11201811807XA SG11201811807XA (en) 2016-07-28 2017-07-28 Dairy product and process
BR112019001525-6A BR112019001525B1 (en) 2016-07-28 2017-07-28 METHOD TO PRODUCE SIALILOLIGOSACCHARIDES, COMPOSITION ENRICHED WITH SIALILOLIGOSACCHARIDE, NUTRITIONAL FORMULATION, EXTRACT CONTAINING SIALILOLIGOSACCHARIDE, AND USE THEREOF
MX2019000881A MX2019000881A (en) 2016-07-28 2017-07-28 Dairy product and process.
US16/319,213 US10729707B2 (en) 2016-07-28 2017-07-28 Dairy product and process
KR1020197001922A KR102502459B1 (en) 2016-07-28 2017-07-28 Dairy Products and Methods
EP17833689.7A EP3490567A4 (en) 2016-07-28 2017-07-28 Dairy product and process
US16/897,117 US20200306277A1 (en) 2016-07-28 2020-06-09 Dairy product and process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ722642 2016-07-28
NZ72264216 2016-07-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/319,213 A-371-Of-International US10729707B2 (en) 2016-07-28 2017-07-28 Dairy product and process
US16/897,117 Continuation US20200306277A1 (en) 2016-07-28 2020-06-09 Dairy product and process

Publications (1)

Publication Number Publication Date
WO2018020473A1 true WO2018020473A1 (en) 2018-02-01

Family

ID=61017021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/054610 WO2018020473A1 (en) 2016-07-28 2017-07-28 Dairy product and process

Country Status (13)

Country Link
US (2) US10729707B2 (en)
EP (1) EP3490567A4 (en)
JP (1) JP2019523278A (en)
KR (1) KR102502459B1 (en)
CN (1) CN109715169A (en)
AU (1) AU2017302181B2 (en)
BR (1) BR112019001525B1 (en)
CA (1) CA3030809A1 (en)
MX (1) MX2019000881A (en)
NZ (1) NZ750365A (en)
RU (1) RU2019105567A (en)
SG (2) SG10202100843TA (en)
WO (1) WO2018020473A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154565A1 (en) 2019-01-24 2020-07-30 Dupont Nutrition Biosciences Aps Process for purifying a human milk oligosaccharide and related compositions
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
WO2020178774A1 (en) * 2019-03-05 2020-09-10 Glycom A/S Human milk oligosaccharides for use in enhancing executive function
BE1027078B1 (en) * 2019-02-25 2020-09-21 Nutribam Bvba COMPOSITION, NUTRITIONAL SUPPLEMENT AND PROCEDURE FOR SUPPORTING AND / OR IMPROVING GUT HEALTH
EP3741770A1 (en) 2019-05-21 2020-11-25 Jennewein Biotechnologie GmbH Purification of oligosaccharides from a fermentation broth by using filtration
CN112203519A (en) * 2018-06-01 2021-01-08 詹尼温生物技术有限责任公司 Simple method for purifying sialyllactose
WO2021124234A1 (en) * 2019-12-19 2021-06-24 Glycom A/S Separation of sialylated oligosaccharides from fermentation broth

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110839698A (en) * 2019-11-29 2020-02-28 内蒙古伊利实业集团股份有限公司 Composition and food application thereof
CA3163651A1 (en) * 2019-12-02 2021-06-10 Avant Meats Company Limited Methods of meat production by in vitro cell cultivation
CN112655774A (en) * 2020-12-25 2021-04-16 石家庄君乐宝乳业有限公司 Infant formula milk powder for promoting brain development and preparation method and application thereof
WO2023025797A1 (en) * 2021-08-24 2023-03-02 Dsm Ip Assets B.V. Human milk oligosaccharides and vitamin b12 composition
WO2023025799A1 (en) * 2021-08-24 2023-03-02 Dsm Ip Assets B.V. Human milk oligosaccahrides in cosmetics
CN114014896B (en) * 2021-10-09 2023-12-05 中国科学院合肥物质科学研究院 Separation and purification method of high-purity 3' -sialyllactose
KR20230119870A (en) 2022-02-08 2023-08-16 주식회사 케이제이엠바이오 Method for preparing a composition for improving brain function and food and pharmaceutical composition for improving brain function
CN114831198B (en) * 2022-05-25 2024-01-30 江南大学 Method for increasing organic acid in Kangpu tea by adding milk permeate powder

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060171A1 (en) * 2000-02-16 2001-08-23 Neose Technologies, Inc. Method of filtration of a dairy stream
US6623954B1 (en) * 2002-05-28 2003-09-23 Neose Technologies, Inc. Process for removal of phosphorous from a dairy stream
US20070104843A1 (en) * 2005-11-04 2007-05-10 Holst Hans H Concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
GB2468670A (en) * 2009-03-17 2010-09-22 Separation Technologies Invest Processing whey or raw milk
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
US20120208782A1 (en) * 2011-02-10 2012-08-16 Wyeth Llc Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk
US20140170293A1 (en) * 2012-12-13 2014-06-19 Arla Foods Amba Concentrate Derived from a Milk Product Enriched in Naturally Occurring Sialyllactose and a Process for Preparation Thereof
WO2015041515A1 (en) * 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
US20150159231A1 (en) * 2013-01-22 2015-06-11 Dmk Deutsches Milchkontor Gmbh Method for increasing the yield in lactose production (ii)
WO2015164021A1 (en) * 2014-04-25 2015-10-29 Mjn U.S. Holdings Llc Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
WO2016146789A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Compostion comprising siallyllactose for use in enhancing learning skills and memory function

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5575916A (en) * 1994-11-07 1996-11-19 Neose Pharmaceuticals, Inc. Method of processing a cheese processing waste stream
JP2997419B2 (en) * 1996-05-31 2000-01-11 雪印乳業株式会社 Brain ganglioside content decrease inhibitor
AU735695B2 (en) 1996-10-10 2001-07-12 Neose Technologies, Inc. Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
DK2241616T3 (en) * 1997-08-21 2013-02-18 New Zealand Dairy Board Immune-enhancing lactic acid bacteria
JPH11180993A (en) * 1997-12-19 1999-07-06 Snow Brand Milk Prod Co Ltd Production of sialic acid
CA2601917C (en) 2005-02-21 2013-12-10 Nestec S.A. Oligosaccharide mixture
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
NL2001377C2 (en) 2008-03-14 2009-09-15 Friesland Brands Bv Process for isolating sialic acid-containing oligosaccharides, as well as the compositions containing sialic acid-containing oligosaccharides.
MY169947A (en) 2008-03-14 2019-06-19 Nestle Sa Preparation of 6-aminocaproic acid from 5-formyl valeri c acid
EP2147678A1 (en) 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
ES2651067T3 (en) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibition of inflammation with milk oligosaccharides
JP5599994B2 (en) 2009-09-29 2014-10-01 雪印メグミルク株式会社 Separation method of sialyl lactose material
JP5641598B2 (en) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 Separation method of sialyl lactose material
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
WO2011112913A1 (en) 2010-03-12 2011-09-15 Martek Biosciences Corporation Maternal sialic acid supplementation
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
SG191393A1 (en) 2010-12-31 2013-08-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
US20120276208A1 (en) 2011-04-27 2012-11-01 University Of South Australia Acute cognitive and mood effects of plant polysaccharides in adult human subjects
JP6106160B2 (en) 2011-05-13 2017-03-29 グリコム アー／エスＧｌｙｃｏｍ Ａ／Ｓ Diversification of human milk oligosaccharide (HMO) or its precursor
EP2526784A1 (en) * 2011-05-24 2012-11-28 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
AU2012325060B2 (en) 2011-10-18 2015-11-19 Nestec S.A. Composition for use in brain growth and/or cognitive and/or psychomotor development
WO2013154725A1 (en) 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
ES2795665T3 (en) 2012-09-14 2020-11-24 Abbott Lab Procedures to increase brain functionality using 2-fucosyl-lactose
AU2013338705B2 (en) * 2012-11-02 2017-06-15 N.V. Nutricia Synbiotics combination for brain improvement
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
EP2934189B1 (en) 2012-12-18 2019-11-06 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
WO2014100191A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Nutritional compositions comprising neuroprotective dietary oligosaccharides
US20160040258A1 (en) * 2013-03-15 2016-02-11 Paul Stephenson Lactose Recovery
ES2875327T3 (en) * 2013-09-10 2021-11-10 Chr Hansen Hmo Gmbh Production of oligosaccharides
CA3013563C (en) 2015-02-04 2023-04-11 Idaho Milk Products Process for manufacture of milk permeate powders
CN109561724A (en) 2016-06-21 2019-04-02 阿拉食品公司 The product for producing the method for the improvement nutrition product containing lactoprotein and lactose class and being obtained by this method

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060171A1 (en) * 2000-02-16 2001-08-23 Neose Technologies, Inc. Method of filtration of a dairy stream
US6623954B1 (en) * 2002-05-28 2003-09-23 Neose Technologies, Inc. Process for removal of phosphorous from a dairy stream
US20070104843A1 (en) * 2005-11-04 2007-05-10 Holst Hans H Concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
GB2468670A (en) * 2009-03-17 2010-09-22 Separation Technologies Invest Processing whey or raw milk
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
US20120208782A1 (en) * 2011-02-10 2012-08-16 Wyeth Llc Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk
US20140170293A1 (en) * 2012-12-13 2014-06-19 Arla Foods Amba Concentrate Derived from a Milk Product Enriched in Naturally Occurring Sialyllactose and a Process for Preparation Thereof
US20150159231A1 (en) * 2013-01-22 2015-06-11 Dmk Deutsches Milchkontor Gmbh Method for increasing the yield in lactose production (ii)
WO2015041515A1 (en) * 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
EP2880993A1 (en) * 2013-12-04 2015-06-10 Abbott Laboratories Method of achieving memory and learning improvement by the administration of sialic acid
WO2015164021A1 (en) * 2014-04-25 2015-10-29 Mjn U.S. Holdings Llc Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
WO2016146789A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Compostion comprising siallyllactose for use in enhancing learning skills and memory function

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Membrane Filtration in the Dairy Industry", GEA PROCESS ENGINEERING, 2012, pages 1 - 20, XP055269252, [retrieved on 20171016] *
ANONYMOUS: "Separation of Milk", DAIR TECHNOLOGY, 16 October 2017 (2017-10-16), pages 1 - 5, XP009518420, Retrieved from the Internet <URL:https://web.archive.org/web/20160216213114/http://dairy-technology.blogspot.com.au/2014/01/separation-of-milk.html> *
See also references of EP3490567A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203519A (en) * 2018-06-01 2021-01-08 詹尼温生物技术有限责任公司 Simple method for purifying sialyllactose
CN112203519B (en) * 2018-06-01 2023-09-15 科汉森母乳低聚糖股份有限公司 Simple method for purifying sialyllactose
WO2020154565A1 (en) 2019-01-24 2020-07-30 Dupont Nutrition Biosciences Aps Process for purifying a human milk oligosaccharide and related compositions
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
BE1027078B1 (en) * 2019-02-25 2020-09-21 Nutribam Bvba COMPOSITION, NUTRITIONAL SUPPLEMENT AND PROCEDURE FOR SUPPORTING AND / OR IMPROVING GUT HEALTH
WO2020178774A1 (en) * 2019-03-05 2020-09-10 Glycom A/S Human milk oligosaccharides for use in enhancing executive function
EP3741770A1 (en) 2019-05-21 2020-11-25 Jennewein Biotechnologie GmbH Purification of oligosaccharides from a fermentation broth by using filtration
WO2020233958A1 (en) 2019-05-21 2020-11-26 Jennewein Biotechnologie Gmbh Purification of oligosaccharides from a fermentation broth by using filtration
WO2021124234A1 (en) * 2019-12-19 2021-06-24 Glycom A/S Separation of sialylated oligosaccharides from fermentation broth

Also Published As

Publication number Publication date
EP3490567A4 (en) 2020-03-18
US20190247409A1 (en) 2019-08-15
KR20190046770A (en) 2019-05-07
US10729707B2 (en) 2020-08-04
NZ750365A (en) 2022-07-01
JP2019523278A (en) 2019-08-22
AU2017302181B2 (en) 2023-02-02
BR112019001525B1 (en) 2022-09-06
US20200306277A1 (en) 2020-10-01
RU2019105567A (en) 2020-08-28
EP3490567A1 (en) 2019-06-05
KR102502459B1 (en) 2023-02-21
CN109715169A (en) 2019-05-03
SG11201811807XA (en) 2019-02-27
MX2019000881A (en) 2019-07-01
CA3030809A1 (en) 2018-02-01
SG10202100843TA (en) 2021-03-30
AU2017302181A1 (en) 2019-02-21
BR112019001525A2 (en) 2019-06-18
RU2019105567A3 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US20200306277A1 (en) Dairy product and process
AU2020230318B2 (en) Composition comprising sialyllactose for use in enhancing learning skills and memory function
RU2568596C2 (en) Lactoferrin and development of healthy brain in babies
US8591981B2 (en) Oligosaccharide mixture
RU2430631C2 (en) Probiotic oligosaccharides mixture and food product containing it
JP2019523278A5 (en)
KR102482040B1 (en) Method for producing an improved nutritional product containing milk proteins and milk sugars and products obtained by the method
AU2021204014B2 (en) Nutritional composition and infant formula for promoting de novo myelination
WO2017167896A1 (en) Compositions comprising minerals and their use
EP3454673B1 (en) Whey preparation for improving brain development
Forsan et al. Novel Nutraceutical Milk Compound in Alzheimer’s Prevention
Gonzalez et al. Advances in Milk Fractionation for Value Addition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17833689

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3030809

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20197001922

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019504767

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019001525

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017302181

Country of ref document: AU

Date of ref document: 20170728

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017833689

Country of ref document: EP

Effective date: 20190228

ENP Entry into the national phase

Ref document number: 112019001525

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190125